Estradiol (medication)

"Altrad" redirects here. For the French corporation "Groupe Altrad", see Mohed Altrad.

This article is about estradiol as a medication. For its role as a hormone, see Estradiol.

Estradiol

Clinical data
Pronunciation	/ˌɛstrəˈdaɪoʊl/ ES-trə-DY-ohl [1] [2]
Trade names	Many
Other names	Oestradiol; E2; 17β-Estradiol; Estra-1,3,5(10)-triene-3,17β-diol
AHFS/Drugs.com	Monograph
License data	US  DailyMed:  Estradiol
Pregnancy category	AU:B1
Routes of administration	By mouth (tablet) • Sublingual (tablet) • Intranasal (nasal spray) • Transdermal (patch, gel, cream, emulsion, spray) • Vaginal (tablet, cream, suppository, insert, ring) • IM injection (oil solution) • SC injection (aq. soln. Tooltip aqueous solution) • Subcutaneous implant
Drug class	Estrogen
ATC code	G03CA03 ( WHO )
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only [3] UK: POM (Prescription only) US: ℞-only EU:Rx-only [4] In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	Oral: <5% [5] IM: 100% [6]
Protein binding	~98%: [5] [7] • Albumin: 60% • SHBG: 38% • Free: 2%
Metabolism	Liver (via hydroxylation, sulfation, glucuronidation)
Metabolites	Major (90%): [5] • Estrone • Estrone sulfate • Estrone glucuronide • Estradiol glucuronide
Elimination half-life	Oral: 13–20 hours [5] Sublingual: 8–18 hours [8] Transdermal (gel): 37 hours [9] IM (as EV Tooltip estradiol valerate): 4–5 days [6] IM (as EC Tooltip estradiol cypionate): 8–10 days [10] IV Tooltip Intravenous injection (as E2): 1–2 hours [6]
Excretion	Urine: 54% [5] Feces: 6% [5]
Identifiers
IUPAC name (8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
CAS Number	50-28-2  Y
PubChem CID	5757
IUPHAR/BPS	1013
DrugBank	DB00783  Y
ChemSpider	5554  Y
UNII	4TI98Z838E
KEGG	D00105  Y
ChEBI	CHEBI:16469  Y
ChEMBL	ChEMBL135  Y
Chemical and physical data
Formula	C18H24O2
Molar mass	272.388 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O
InChI InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1 Y Key:VOXZDWNPVJITMN-ZBRFXRBCSA-N Y
(verify)

Estradiol (E2) is a medication and naturally occurring steroid hormone. ^{[11] [12] [13]} It is an estrogen and is used mainly in menopausal hormone therapy and to treat low sex hormone levels in women. ^{[11] [14]} It is also used in hormonal birth control for women, in feminizing hormone therapy for transgender women, and in the treatment of hormone-sensitive cancers like prostate cancer in men and breast cancer in women, among other uses. ^{[15] [16] [17] [18] [19]} Estradiol can be taken by mouth, held and dissolved under the tongue, as a gel or patch that is applied to the skin, in through the vagina, by injection into muscle or fat, or through the use of an implant that is placed into fat, among other routes. ^[11]

Side effects of estradiol in women include breast tenderness, breast enlargement, headache, fluid retention, and nausea among others. ^{[11] [20]} Men and children who are exposed to estradiol may develop symptoms of feminization, such as breast development and a feminine pattern of fat distribution, and men may also experience low testosterone levels and infertility. ^{[21] [22]} Estradiol may increase the risk of endometrial hyperplasia and endometrial cancer in women with intact uteruses if it is not taken together with a progestogen such as progesterone. ^[11] The combination of estradiol with a progestin, though not with oral progesterone, may increase the risk of breast cancer. ^{[23] [24]} Estradiol should not be used in women who are pregnant or breastfeeding or who have breast cancer, among other contraindications. ^[20]

Estradiol is a naturally occurring and bioidentical estrogen, or an agonist of the estrogen receptor, the biological target of estrogens like endogenous estradiol. ^[11] Due to its estrogenic activity, estradiol has antigonadotropic effects and can inhibit fertility and suppress sex hormone production in both women and men. ^{[25] [26]} Estradiol differs from non-bioidentical estrogens like conjugated estrogens and ethinylestradiol in various ways, with implications for tolerability and safety. ^[11]

Estradiol was discovered in 1933. ^{[27] [28]} It became available as a medication that same year, in an injectable form known as estradiol benzoate. ^{[29] [30] [31]} Forms that were more useful by mouth, estradiol valerate and micronized estradiol, were introduced in the 1960s and 1970s and increased its popularity by this route. ^{[32] [33] [34]} Estradiol is also used as other prodrugs, like estradiol cypionate. ^[11] Related estrogens such as ethinylestradiol, which is the most common estrogen in birth control pills, and conjugated estrogens (brand name Premarin), which is used in menopausal hormone therapy, are used as medications as well. ^[11] In 2022, it was the 50th most commonly prescribed medication in the United States, with more than 12 million prescriptions. ^{[35] [36]} It is available as a generic medication. ^{[37] [38] [39]}

Medical uses

Hormone therapy

Menopause

See also: Menopausal hormone therapy

Average number of moderate-to-severe hot flashes per week with placebo and different doses of oral estradiol in menopausal women

Estradiol is used in menopausal hormone therapy to prevent and treat moderate to severe menopausal symptoms such as hot flashes, vaginal dryness and atrophy, and osteoporosis (bone loss). ^[11] As unopposed estrogen therapy (using estrogen alone without progesterone) increases the risk of endometrial hyperplasia and endometrial cancer in women with intact uteruses, estradiol is usually combined with a progestogen like progesterone or medroxyprogesterone acetate to prevent the effects of estradiol on the endometrium. ^{[11] [42]} This is not necessary if the woman has undergone a hysterectomy (surgical removal of the uterus). ^[11] A 2017 meta-analysis found that estradiol had no effect on depressive symptoms in peri- and postmenopausal women. ^[43]

• v
• t
• e

Estrogen dosages for menopausal hormone therapy

Route/form	Estrogen	Low	Standard	High
Oral	Estradiol	0.5–1 mg/day	1–2 mg/day	2–4 mg/day
	Estradiol valerate	0.5–1 mg/day	1–2 mg/day	2–4 mg/day
	Estradiol acetate	0.45–0.9 mg/day	0.9–1.8 mg/day	1.8–3.6 mg/day
	Conjugated estrogens	0.3–0.45 mg/day	0.625 mg/day	0.9–1.25 mg/day
	Esterified estrogens	0.3–0.45 mg/day	0.625 mg/day	0.9–1.25 mg/day
	Estropipate	0.75 mg/day	1.5 mg/day	3 mg/day
	Estriol	1–2 mg/day	2–4 mg/day	4–8 mg/day
	Ethinylestradiol a	2.5–10 μg/day	5–20 μg/day	–
Nasal spray	Estradiol	150 μg/day	300 μg/day	600 μg/day
Transdermal patch	Estradiol	25 μg/dayb	50 μg/dayb	100 μg/dayb
Transdermal gel	Estradiol	0.5 mg/day	1–1.5 mg/day	2–3 mg/day
Vaginal	Estradiol	25 μg/day	–	–
	Estriol	30 μg/day	0.5 mg 2x/week	0.5 mg/day
IM Tooltip Intramuscular or SC injection	Estradiol valerate	–	–	4 mg 1x/4 weeks
	Estradiol cypionate	1 mg 1x/3–4 weeks	3 mg 1x/3–4 weeks	5 mg 1x/3–4 weeks
	Estradiol benzoate	0.5 mg 1x/week	1 mg 1x/week	1.5 mg 1x/week
SC implant	Estradiol	25 mg 1x/6 months	50 mg 1x/6 months	100 mg 1x/6 months
Footnotes:a = No longer used or recommended, due to health concerns. b = As a single patch applied once or twice per week (worn for 3–4 days or 7 days), depending on the formulation. Note: Dosages are not necessarily equivalent. Sources: See template.

Hypogonadism

Estrogen is responsible for the mediation of puberty in females, and in girls with delayed puberty due to hypogonadism (low-functioning gonads, which can result in low sex hormone levels) such as in Turner syndrome, estradiol is used to induce the development of and maintain female secondary sexual characteristics such as breasts, wide hips, and a female fat distribution. ^{[44] [14] [45]} It is also used to restore estradiol levels in adult premenopausal women with hypogonadism, for instance those with premature ovarian failure or who have undergone oophorectomy. ^{[14] [45]} It is used to treat women with hypogonadism due to hypopituitarism as well. ^{[45] [14]}

Transgender women

Main article: Feminizing hormone therapy

Estradiol is used as part of feminizing hormone therapy for transgender women. ^{[46] [17]} The drug is used in higher dosages prior to gender-affirming surgery or orchiectomy to help suppress testosterone levels; after this procedure, estradiol continues to be used at lower dosages to maintain estradiol levels in the normal premenopausal female range. ^{[46] [17]}

Birth control

Although almost all combined oral contraceptives contain the synthetic estrogen ethinylestradiol, ^[47] natural estradiol itself is also used in some hormonal contraceptives, including in estradiol-containing oral contraceptives and combined injectable contraceptives. ^{[15] [16]} It is formulated in combination with a progestin such as dienogest, nomegestrol acetate, or medroxyprogesterone acetate, and is often used in the form of an ester prodrug like estradiol valerate or estradiol cypionate. ^{[15] [16]} Hormonal contraceptives contain a progestin and/or estrogen and prevent ovulation and thus the possibility of pregnancy by suppressing the secretion of the gonadotropins follicle-stimulating hormone (FSH) and luteinizing hormone (LH), the peak of which around the middle of the menstrual cycle causes ovulation to occur. ^[48]

Hormonal cancer

Prostate cancer

Estradiol is used as a form of high-dose estrogen therapy to treat prostate cancer and is similarly effective to other therapies such as androgen deprivation therapy with castration and antiandrogens. ^{[18] [13] [49] [50]} It is used in the form of long-lasting injected estradiol prodrugs like polyestradiol phosphate, estradiol valerate, and estradiol undecylate, ^{[13] [49] [51]} and has also more recently been assessed in the form of transdermal estradiol patches. ^{[49] [52]} Estrogens are effective in the treatment of prostate cancer by suppressing testosterone levels into the castrate range, increasing levels of sex hormone-binding globulin (SHBG) and thereby decreasing the fraction of free testosterone, and possibly also via direct cytotoxic effects on prostate cancer cells. ^{[53] [54] [55]} Parenteral estradiol is largely free of the cardiovascular side effects of the high oral dosages of synthetic estrogens like diethylstilbestrol ad ethinylestradiol that were used previously. ^{[49] [56] [57]} In addition, estrogens may have advantages relative to castration in terms of hot flashes, sexual interest and function, osteoporosis, cognitive function, and quality of life. ^{[49] [57] [54] [58]} However, side effects such as gynecomastia and feminization in general may be difficult to tolerate and unacceptable for many men. ^[49]

Breast cancer

High-dose estrogen therapy is effective in the treatment of about 35% of cases of breast cancer in women who are at least 5 years menopausal and has comparable effectiveness to antiestrogen therapy with medications like the selective estrogen receptor modulator (SERM) tamoxifen. ^{[19] [59] [60]} Although estrogens are rarely used in the treatment of breast cancer today and synthetic estrogens like diethylstilbestrol and ethinylestradiol have most commonly been used, estradiol itself has been used in the treatment of breast cancer as well. ^{[19] [20] [61]} It has been used orally at very high doses (30 mg/day) in the treatment of therapy-naive breast cancer and orally at low doses (2 to 6 mg/day) in the treatment of breast cancer in women who were previously treated with and benefited from but acquired resistance to aromatase inhibitors. ^{[19] [62] [20]} Polyestradiol phosphate is also used to treat breast cancer. ^{[63] [64]}

Other uses

Infertility

Estrogens may be used in treatment of infertility in women when there is a need to develop sperm-friendly cervical mucus or an appropriate uterine lining. ^{[65] [66]}

It is also commonly used during in vitro fertilization (IVF). Estrogen helps maintain the endometrial lining of the uterus and help prepare for pregnancy. Research shows higher pregnancy rate if the mother takes estrogen in addition to progesterone. ^[67] Estradiol is the predominant form of estrogen during reproductive years and is most commonly prescribed. ^[67]

Lactation suppression

Estrogens can be used to suppress and cease lactation and breast engorgement in postpartum women who do not wish to breastfeed. ^{[68] [59]} They do this by directly decreasing the sensitivity of the alveoli of the mammary glands to the lactogenic hormone prolactin. ^[59]

Tall stature

Estrogens have been used to limit final height in adolescent girls with tall stature. ^[69] They do this by inducing epiphyseal closure and suppressing growth hormone-induced hepatic production and by extension circulating levels of insulin-like growth factor-1 (IGF-1), a hormone that causes the body to grow and increase in size. ^[69] Although ethinylestradiol and conjugated estrogens have mainly been used for this purpose, estradiol can also be employed. ^{[70] [71]}

Breast enhancement

Estrogens are involved in breast development and estradiol may be used as a form of hormonal breast enhancement to increase the size of the breasts. ^{[72] [73] [74] [75] [76]} Both polyestradiol phosphate monotherapy and pseudopregnancy with a combination of high-dosage intramuscular estradiol valerate and hydroxyprogesterone caproate have been assessed for this purpose in clinical studies. ^{[72] [73] [74] [75]} However, acute or temporary breast enlargement is a well-known side effect of estrogens, and increases in breast size tend to regress following discontinuation of treatment. ^{[72] [74] [75]} Aside from those without prior established breast development, evidence is lacking for a sustained increases in breast size with estrogens. ^{[72] [74] [75]}

Schizophrenia

Estradiol has been found to be effective in the adjunctive treatment of schizophrenia in women. ^{[77] [78] [79]} It has been found to significantly reduce positive, negative, and cognitive symptoms, with particular benefits on positive symptoms. ^{[77] [78] [79] [80]} Other estrogens, as well as selective estrogen receptor modulators (SERMs) like raloxifene, have been found to be effective in the adjunctive treatment of schizophrenia in women similarly. ^{[77] [81] [82]} Estrogens may be useful in the treatment of schizophrenia in men as well, but their use in this population is limited by feminizing side effects. ^[83] SERMs, which have few or no feminizing side effects, have been found to be effective in the adjunctive treatment of schizophrenia in men similarly to in women and may be more useful than estrogens in this sex. ^{[81] [82]}

Sexual deviance

Estradiol has been used at high doses to suppress sex drive in men with sexual deviance such as paraphilias and in sex offenders. ^{[84] [85] [86]} It has specifically been used for this indication in the forms of intramuscular injections of estradiol valerate and estradiol undecylate and of subcutaneous pellet implants of estradiol. ^{[84] [85] [86]}

Available forms

• v
• t
• e

Available forms of estradiol ^{[lower-alpha 1]}

Route	Ingredient	Form	Dose [lower-alpha 2]	Brand names [lower-alpha 3]
Oral	Estradiol	Tablet	0.1, 0.2, 0.5, 1, 2, 4 mg	Estrace, Ovocyclin
	Estradiol valerate	Tablet	0.5, 1, 2, 4 mg	Progynova
Transdermal	Estradiol	Patch	14, 25, 37.5, 50, 60, 75, 100 µg/d	Climara, Vivelle
		Gel pump	0.06% (0.52, 0.75 mg/pump)	Elestrin, EstroGel
		Gel packet	0.1% (0.25, 0.5, 1.0 mg/pk.)	DiviGel, Sandrena
		Emulsion	0.25% (25 µg/pouch)	Estrasorb
		Spray	1.53 mg/spray	Evamist, Lenzetto
Vaginal	Estradiol	Tablet	10, 25 µg	Vagifem
		Cream	0.01% (0.1 mg/gram)	Estrace
		Insert	4, 10 µg	Imvexxy
		Ring	2 mg/ring (7.5 µg/d, 3 mon.)	Estring
	Estradiol acetate	Ring	50, 100 µg/d, 3 months	Femring
Injection [lower-alpha 4]	Estradiol	Microspheres	1 mg/mL	Juvenum E
	Estradiol benzoate	Oil solution	0.167, 0.2, 0.333, 1, 1.67, 2, 5, 10, 20, 25 mg/mL	Progynon-B
	Estradiol cypionate	Oil solution	1, 3, 5 mg/mL	Depo-Estradiol
	Estradiol valerate	Oil solution	5, 10, 20, 40 mg/mL	Progynon Depot
Implant	Estradiol	Pellet	20, 25, 50, 100 mg, 6 mon.	Estradiol Implants
Notes and sources: This table includes primarily products available as a single-ingredient estradiol preparation—thus excluding compounds with progestogens or other ingredients included. The table furthermore does not include compounded drugs—only commercially produced products. Availability of each product varies by country. Doses are given per unit (ex: per tablet, per mL). Other brand names may be manufactured or previously manufactured. By intramuscular or subcutaneous injection. Sources: [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100]

Estradiol is available in a variety of different formulations, including oral, intranasal, transdermal/topical, vaginal, injectable, and implantable preparations. ^{[11] [101]} An ester may be attached to one or both of the hydroxyl groups of estradiol to improve its oral bioavailability and/or duration of action with injection. ^[11] Such modifications give rise to forms such as estradiol acetate (oral and vaginal), estradiol valerate (oral and injectable), estradiol cypionate (injectable), estradiol benzoate (injectable), estradiol undecylate (injectable), and polyestradiol phosphate (injectable; a polymerized ester of estradiol), which are all prodrugs of estradiol. ^{[11] [101] [102]}

Gallery of available forms of estradiol

• 
  Progynova (estradiol valerate) 2 mg oral tablets.
• 
  Generic estradiol (Mylan) 100 μg/day once-weekly transdermal patches.
• 
  Vivelle-Dot (estradiol) 100 μg/day twice-weekly transdermal patches.
• 
  EstroGel 0.06% (estradiol) once-daily hydroalcoholic transdermal gel. Delivers 0.75 mg estradiol per pump.
• 
  Depo-Estradiol 5 mg/mL (estradiol cypionate in oil solution) vials. Used by depot intramuscular injection.

Contraindications

Estrogens like estradiol have a number of contraindications. ^{[103] [28] [104] [105]} Estradiol should be avoided when there is undiagnosed abnormal vaginal bleeding, known, suspected or a history of breast cancer, current treatment for metastatic disease, known or suspected estrogen-dependent neoplasia, deep vein thrombosis, pulmonary embolism or history of these conditions, active or recent arterial thromboembolic disease such as stroke, myocardial infarction, liver dysfunction or disease. Estradiol should not be taken by people with a hypersensitivity/allergy or those who are pregnant or are suspected pregnant. ^[20]

Side effects

See also: Estrogen (medication) § Side effects, and List of side effects of estradiol

Common side effects of estradiol in women include headache, breast pain or tenderness, breast enlargement, irregular vaginal bleeding or spotting, abdominal cramps, bloating, fluid retention, and nausea. ^{[20] [106] [107] [5]} Other possible side effects of estrogens may include high blood pressure, high blood sugar, enlargement of uterine fibroids, melasma, vaginal yeast infections, and liver problems. ^[20] In men, estrogens can cause breast pain or tenderness, gynecomastia (male breast development), feminization, demasculinization, sexual dysfunction (decreased libido and erectile dysfunction), hypogonadism, testicular atrophy, and infertility. ^{[21] [22]}

• v
• t
• e

Side effects of lower versus higher dose oral estradiol

Serious adverse event	Estradiol Tooltip Estradiol_(medication) 6 mg/day (n = 34)		Estradiol Tooltip Estradiol_(medication) 30 mg/day (n = 32)
	n	%	n	%
Nausea/vomiting	0	0.0	5	15.6
Hyponatremia	1	2.9	5	15.6
Pleural effusion	0	0.0	4	12.5
Pain	6	17.6	4	12.5
Thrombosis/embolism	1	2.9	1	3.1
Brain ischemia	1	2.9	0	0.0
Infection	2	5.9	3	9.4
Hypercalcemia	0	0.0	2	6.3
Other	6	17.6	10	31.3
Summary: Side effects in a small phase 2 study of women with metastatic breast cancer randomized to receive either 6 or 30 mg/day of oral estradiol Tooltip Pharmacokinetics_of_estradiol#Oral_administration as therapy. "The adverse event rate (≥grade 3) in the 30-mg group (11/32 [34%]; 95% confidence interval [CI], 23%-47%) was higher than in the 6-mg group (4/34 [18%]; 95% CI, 5%-22%; p=0.03). Clinical benefit rates were 9 of 32 (28%; 95% CI, 18%-41%) in the 30-mg group and 10 of 34 (29%; 95% CI, 19%-42%) in the 6-mg group." Sources: See template.

Blood clots

See also: Estrogen (medication) § Cardiovascular events

Oral estradiol and estradiol valerate, for instance in menopausal hormone therapy or birth control pills, are associated with a significantly higher risk of venous thromboembolism (VTE) than non-use. ^{[108] [109] [110] [111]} Higher doses of oral estrogens are associated with higher risks of VTE. ^{[110] [112] [113]} In contrast to oral estradiol, transdermal and vaginal estradiol at menopausal replacement dosages are not associated with a higher incidence of VTE. ^{[108] [109] [114] [110]} Low doses (e.g., 50 μg/day) and high doses (e.g., 100 μg/day) of transdermal estradiol for menopausal replacement do not differ in terms of VTE risk. ^{[115] [114] [116] [110]} The higher risk of VTE with oral estradiol can be attributed to the first pass and a disproportionate effect on liver synthesis of coagulation factors. ^{[11] [117]} Even high doses of parenteral estradiol, such as high-dose polyestradiol phosphate, have minimal influence on coagulation factors, in contrast to oral estrogen therapy. ^{[57] [49] [118]} However, sufficient doses of parenteral estradiol, for instance very high doses of estradiol valerate by intramuscular injection, can nonetheless activate coagulation, presumably increasing VTE risk. ^{[119] [120]}

In addition to the route of administration, the type of estrogen influences VTE risk. ^{[121] [117]} Oral conjugated estrogens are associated with a higher risk of VTE than oral estradiol. ^{[122] [116] [123]} Estradiol- and estradiol valerate-containing birth control pills are associated with a lower risk of VTE than birth control pills containing ethinylestradiol. ^{[111] [117]} The relative risk of VTE is thought to be highest with oral ethinylestradiol, intermediate with oral conjugated estrogens, low with oral estradiol and parenteral estradiol valerate, and very low with transdermal estradiol. ^[121] Conjugated estrogens and ethinylestradiol are thought to have a higher risk of VTE than estradiol because they are resistant to hepatic metabolism and have a disproportionate influence on liver production of coagulation factors. ^{[11] [121] [117]}

The combination of oral or transdermal estradiol and a progestin is associated with a higher risk of VTE than estradiol alone. ^{[109] [124]} Dydrogesterone is associated with a lower risk than other progestins such as medroxyprogesterone acetate and norethisterone, while oral progesterone is associated with no increase in risk of VTE. ^{[109] [110]} Older age, higher body weight, lower physical activity, and smoking are all associated with a higher risk of VTE with oral estrogen therapy. ^{[117] [125] [124] [112]} Risk of VTE with estrogen therapy is highest at the start of treatment, particularly during the first year, and decreases over time. ^{[117] [124]}

The absolute risk of VTE with estrogen and/or progestin therapy is small. ^{[126] [127] [124]} Women who are not on a birth control pill or hormone therapy have a risk of VTE of about 1 to 5 out of 10,000 women per year. ^{[126] [127] [116] [124]} In women taking a birth control pill containing ethinylestradiol and a progestin, the risk of VTE is in the range of 3 to 10 out of 10,000 women per year. ^{[126] [127] [124]} Birth control pills containing estradiol valerate and a progestin are associated with about half the risk of VTE of ethinylestradiol/progestin-containing birth control pills. ^{[111] [128]} Hormone therapy for transgender women likewise is associated with a lower risk of VTE than birth control pills containing ethinylestradiol and a progestin. ^{[129] [121]} The risk of VTE during pregnancy, when estrogens and progesterone increase to very high levels, is 5 to 20 in 10,000 women per year, while the risk is 40 to 65 per 10,000 women per year during the postpartum period. ^{[127] [124]}

• v
• t
• e

Risk of venous thromboembolism (VTE) with hormone therapy and birth control (QResearch/CPRD)

Type	Route	Medications	Odds ratio (95% CI Tooltip confidence interval)
Menopausal hormone therapy	Oral	Estradiol alone     ≤1 mg/day     >1 mg/day	1.27 (1.16–1.39)* 1.22 (1.09–1.37)* 1.35 (1.18–1.55)*
		Conjugated estrogens alone     ≤0.625 mg/day     >0.625 mg/day	1.49 (1.39–1.60)* 1.40 (1.28–1.53)* 1.71 (1.51–1.93)*
		Estradiol/medroxyprogesterone acetate	1.44 (1.09–1.89)*
		Estradiol/dydrogesterone     ≤1 mg/day E2     >1 mg/day E2	1.18 (0.98–1.42) 1.12 (0.90–1.40) 1.34 (0.94–1.90)
		Estradiol/norethisterone     ≤1 mg/day E2     >1 mg/day E2	1.68 (1.57–1.80)* 1.38 (1.23–1.56)* 1.84 (1.69–2.00)*
		Estradiol/norgestrel or estradiol/drospirenone	1.42 (1.00–2.03)
		Conjugated estrogens/medroxyprogesterone acetate	2.10 (1.92–2.31)*
		Conjugated estrogens/norgestrel     ≤0.625 mg/day CEEs     >0.625 mg/day CEEs	1.73 (1.57–1.91)* 1.53 (1.36–1.72)* 2.38 (1.99–2.85)*
		Tibolone alone	1.02 (0.90–1.15)
		Raloxifene alone	1.49 (1.24–1.79)*
	Transdermal	Estradiol alone    ≤50 μg/day    >50 μg/day	0.96 (0.88–1.04) 0.94 (0.85–1.03) 1.05 (0.88–1.24)
		Estradiol/progestogen	0.88 (0.73–1.01)
	Vaginal	Estradiol alone	0.84 (0.73–0.97)
		Conjugated estrogens alone	1.04 (0.76–1.43)
Combined birth control	Oral	Ethinylestradiol/norethisterone	2.56 (2.15–3.06)*
		Ethinylestradiol/levonorgestrel	2.38 (2.18–2.59)*
		Ethinylestradiol/norgestimate	2.53 (2.17–2.96)*
		Ethinylestradiol/desogestrel	4.28 (3.66–5.01)*
		Ethinylestradiol/gestodene	3.64 (3.00–4.43)*
		Ethinylestradiol/drospirenone	4.12 (3.43–4.96)*
		Ethinylestradiol/cyproterone acetate	4.27 (3.57–5.11)*
Notes: (1) Nested case–control studies (2015, 2019) based on data from the QResearch and Clinical Practice Research Datalink (CPRD) databases. (2) Bioidentical progesterone was not included, but is known to be associated with no additional risk relative to estrogen alone. Footnotes: * = Statistically significant (p < 0.01). Sources: See template.

Long-term effects

Uncommon but serious possible side effects of estrogens associated with long-term therapy may include breast cancer, uterine cancer, stroke, heart attack, blood clots, dementia, gallbladder disease, and ovarian cancer. ^[34] Warning signs of these serious side effects include breast lumps, unusual vaginal bleeding, dizziness, faintness, changes in speech, severe headaches, chest pain, shortness of breath, pain in the legs, changes in vision, and vomiting. ^[34]

Due to health risks observed with the combination of conjugated estrogens and medroxyprogesterone acetate in the Women's Health Initiative (WHI) studies (see below), the US Food and Drug Administration (FDA) label for Estrace (estradiol) advises that estrogens should be used in menopausal hormone therapy only for the shortest time possible and at the lowest effective dose. ^[20] While the FDA states that is unknown if these risks generalize to estradiol (alone or in combination with progesterone or a progestin), it advises that in the absence of comparable data, the risks should be assumed to be similar. ^[20] When used to treat menopausal symptoms, the FDA recommends that discontinuation of estradiol should be attempted every three to six months via a gradual dose taper. ^[20]

The combination of bioidentical transdermal or vaginal estradiol and oral or vaginal progesterone appears to be a safer form of hormone therapy than the combination of oral conjugated estrogens and medroxyprogesterone acetate and may not share the same health risks. ^{[130] [131] [132] [133] [134] [135] [136] [137] [125]} Advantages may include reduced or no risk of venous thromboembolism, cardiovascular disease, and breast cancer, among others. ^{[130] [131] [132] [133] [134] [135] [136] [137] [125]}

• v
• t
• e

Results of the Women's Health Initiative (WHI) menopausal hormone therapy randomized controlled trials

Clinical outcome	Hypothesized effect on risk	Estrogen and progestogen (CEs Tooltip conjugated estrogens 0.625 mg/day p.o. + MPA Tooltip medroxyprogesterone acetate 2.5 mg/day p.o.) (n = 16,608, with uterus, 5.2–5.6 years follow up)			Estrogen alone (CEs Tooltip Conjugated estrogens 0.625 mg/day p.o.) (n = 10,739, no uterus, 6.8–7.1 years follow up)
		HR Tooltip Hazard ratio	95% CI Tooltip Confidence interval	AR Tooltip Attributable risk	HR Tooltip Hazard ratio	95% CI Tooltip Confidence interval	AR Tooltip Attributable risk
Coronary heart disease	Decreased	1.24	1.00–1.54	+6 / 10,000 PYs	0.95	0.79–1.15	−3 / 10,000 PYs
Stroke	Decreased	1.31	1.02–1.68	+8 / 10,000 PYs	1.37	1.09–1.73	+12 / 10,000 PYs
Pulmonary embolism	Increased	2.13	1.45–3.11	+10 / 10,000 PYs	1.37	0.90–2.07	+4 / 10,000 PYs
Venous thromboembolism	Increased	2.06	1.57–2.70	+18 / 10,000 PYs	1.32	0.99–1.75	+8 / 10,000 PYs
Breast cancer	Increased	1.24	1.02–1.50	+8 / 10,000 PYs	0.80	0.62–1.04	−6 / 10,000 PYs
Colorectal cancer	Decreased	0.56	0.38–0.81	−7 / 10,000 PYs	1.08	0.75–1.55	+1 / 10,000 PYs
Endometrial cancer	–	0.81	0.48–1.36	−1 / 10,000 PYs	–	–	–
Hip fractures	Decreased	0.67	0.47–0.96	−5 / 10,000 PYs	0.65	0.45–0.94	−7 / 10,000 PYs
Total fractures	Decreased	0.76	0.69–0.83	−47 / 10,000 PYs	0.71	0.64–0.80	−53 / 10,000 PYs
Total mortality	Decreased	0.98	0.82–1.18	−1 / 10,000 PYs	1.04	0.91–1.12	+3 / 10,000 PYs
Global index	–	1.15	1.03–1.28	+19 / 10,000 PYs	1.01	1.09–1.12	+2 / 10,000 PYs
Diabetes	–	0.79	0.67–0.93		0.88	0.77–1.01
Gallbladder disease	Increased	1.59	1.28–1.97		1.67	1.35–2.06
Stress incontinence	–	1.87	1.61–2.18		2.15	1.77–2.82
Urge incontinence	–	1.15	0.99–1.34		1.32	1.10–1.58
Peripheral artery disease	–	0.89	0.63–1.25		1.32	0.99–1.77
Probable dementia	Decreased	2.05	1.21–3.48		1.49	0.83–2.66
Abbreviations: CEs = conjugated estrogens. MPA = medroxyprogesterone acetate. p.o. = per oral. HR = hazard ratio. AR = attributable risk. PYs = person–years. CI = confidence interval. Notes: Sample sizes (n) include placebo recipients, which were about half of patients. "Global index" is defined for each woman as the time to earliest diagnosis for coronary heart disease, stroke, pulmonary embolism, breast cancer, colorectal cancer, endometrial cancer (estrogen plus progestogen group only), hip fractures, and death from other causes. Sources: See template.

Overdose

Estrogens are relatively safe in overdose. ^[102] During pregnancy, levels of estradiol increase to very high concentrations that are as much as 100-fold normal levels. ^{[138] [139] [140]} In late pregnancy, the body produces and secretes approximately 100 mg of estrogens, including estradiol, estrone, and estriol, per day. ^[138] Doses of estradiol of as high as 200 mg per day by intramuscular injection for several weeks have been administered to humans in studies. ^{[141] [142]} Serious adverse effects have not been described following acute overdose of large doses of estrogen- and progestogen-containing birth control pills by small children. ^[102] Symptoms of estrogen overdosage may include nausea, vomiting, bloating, increased weight, water retention, breast tenderness, vaginal discharge, vaginal bleeding, heavy legs, and leg cramps. ^{[103] [102]}

Interactions

Inducers of cytochrome P450 enzymes like CYP3A4 such as St. John's wort, phenobarbital, carbamazepine and rifampicin decrease the circulating levels of estradiol by accelerating its metabolism, whereas inhibitors of cytochrome P450 enzymes like CYP3A4 such as erythromycin, cimetidine, ^[143] clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice ^[144] may slow its metabolism resulting in increased levels of estradiol in the circulation. ^[20] There is an interaction between estradiol and alcohol such that alcohol considerably increases circulating levels of estradiol during oral estradiol therapy and also increases estradiol levels in normal premenopausal women and with parenteral estradiol therapy. ^{[145] [13] [146] [147]} This appears to be due to a decrease in hepatic 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) activity and hence estradiol inactivation into estrone due to an alcohol-mediated increase in the ratio of NADH to NAD in the liver. ^{[146] [147]} Spironolactone may reduce the bioavailability of high doses of oral estradiol. ^[148]

Pharmacology

Pharmacodynamics

Main article: Pharmacodynamics of estradiol

Estradiol is an estrogen, or an agonist of the estrogen receptors (ERs), the ERα Tooltip estrogen receptor alpha and ERβ Tooltip estrogen receptor beta. ^[11] It is also an agonist of membrane estrogen receptors (mERs), including the GPER Tooltip G protein-coupled estrogen receptor, G_q-mER Tooltip Gq-coupled membrane estrogen receptor, ER-X, and ERx. ^{[149] [150]} Estradiol is highly selective for these ERs and mERs, and does not interact importantly with other steroid hormone receptors. ^{[151] [152] [153]} It is far more potent as an estrogen than are other bioidentical estrogens like estrone and estriol. ^{[11] [154]} Given by subcutaneous injection in mice, estradiol is about 10-fold more potent than estrone and about 100-fold more potent than estriol. ^[154]

The ERs are expressed widely throughout the body, including in the breasts, uterus, vagina, fat, skin, bone, liver, pituitary gland, hypothalamus, and other parts of the brain. ^[27] In accordance, estradiol has numerous effects throughout the body. ^{[27] [155] [156] [157] [158] [159] [160] [13] [53] [161] [162] [163] [164]} Among other effects, estradiol produces breast development, feminization, changes in the female reproductive system, changes in liver protein synthesis, and changes in brain function. ^{[159] [160] [13] [53] [161] [162] [163] [164]} The effects of estradiol can influence health in both positive and negative ways. ^[11] In addition to the aforementioned effects, estradiol has antigonadotropic effects due to its estrogenic activity, and can inhibit ovulation and suppress gonadal sex hormone production. ^{[160] [13] [53] [54] [55] [25] [26]} At sufficiently high dosages, estradiol is a powerful antigonadotropin, capable of suppressing testosterone levels into the castrate/female range in men. ^{[53] [54] [55] [25] [26]}

There are differences between estradiol and other estrogens, such as non-bioidentical estrogens like natural conjugated estrogens and synthetic estrogens like ethinylestradiol and diethylstilbestrol, with implications for pharmacodynamics and pharmacokinetics as well as efficacy, tolerability, and safety. ^[11]

Pharmacokinetics

Main article: Pharmacokinetics of estradiol

Estradiol can be taken by a variety of different routes of administration. ^[11] These include oral, buccal, sublingual, intranasal, transdermal (gels, creams, patches), vaginal (tablets, creams, rings, suppositories), rectal, by intramuscular or subcutaneous injection (in oil or aqueous), and as a subcutaneous implant. ^[11] The pharmacokinetics of estradiol, including its bioavailability, metabolism, biological half-life, and other parameters, differ by route of administration. ^[11] Likewise, the potency of estradiol, and its local effects in certain tissues, most importantly the liver, differ by route of administration as well. ^[11] In particular, the oral route is subject to a high first-pass effect, which results in high levels of estradiol and consequent estrogenic effects in the liver and low potency due to first-pass hepatic and intestinal metabolism into metabolites like estrone and estrogen conjugates. ^[11] Conversely, this is not the case for parenteral (non-oral) routes, which bypass the intestines and liver. ^[11]

Different estradiol routes and dosages can achieve widely varying circulating estradiol levels. ^[11] For purposes of comparison with normal physiological circumstances, menstrual cycle circulating levels of estradiol in premenopausal women are 40 pg/mL in the early follicular phase, 250 pg/mL at the middle of the cycle, and 100 pg/mL during the mid-luteal phase. ^[163] Mean integrated levels of circulating estradiol in premenopausal women across the whole menstrual cycle have been reported to be in the range of 80 and 150 pg/mL, according to some sources. ^{[165] [166] [167]}

Chemistry

v t e Structures of major endogenous estrogens Estrone (E1) Estradiol (E2) Estriol (E3) Estetrol (E4) Note the hydroxyl (–OH) groups: estrone (E1) has one, estradiol (E2) has two, estriol (E3) has three, and estetrol (E4) has four.

Estradiol is a naturally occurring estrane steroid. ^{[11] [168]} It is also known as 17β-estradiol (to distinguish it from 17α-estradiol) or as estra-1,3,5(10)-triene-3,17β-diol. ^{[169] [170] [11]} It has two hydroxyl groups, one at the C3 position and the other at the C17β position, as well as three double bonds in the A ring (the estra-1,3,5(10)-triene core). ^{[168] [171]} Due to its two hydroxyl groups, estradiol is often abbreviated as E2. ^[168] The structurally related estrogens, estrone (E1), estriol (E3), and estetrol (E4) have one, three, and four hydroxyl groups, respectively. ^{[168] [172]}

Hemihydrate

A hemihydrate form of estradiol, estradiol hemihydrate, is widely used medically under a large number of brand names similarly to estradiol. ^[170] In terms of activity and bioequivalence, estradiol and its hemihydrate are identical, with the only disparities being an approximate 3% difference in potency by weight (due to the presence of water molecules in the hemihydrate form of the substance) and a slower rate of release with certain formulations of the hemihydrate. ^{[173] [174]} This is because estradiol hemihydrate is more hydrated than anhydrous estradiol, and for this reason, is more insoluble in water in comparison, which results in slower absorption rates with specific formulations of the drug such as vaginal tablets. ^[174] Estradiol hemihydrate has also been shown to result in less systemic absorption as a vaginal tablet formulation relative to other topical estradiol formulations such as vaginal creams. ^[175] Estradiol hemihydrate is used in place of estradiol in some estradiol products. ^{[176] [177] [178]}

Derivatives

See also: List of estrogens § Estradiol derivatives, Estrogen ester, and List of estrogen esters § Estradiol esters

A variety of C17β and/or C3 ester prodrugs of estradiol, such as estradiol acetate, estradiol benzoate, estradiol cypionate, estradiol dipropionate, estradiol enantate, estradiol undecylate, estradiol valerate, and polyestradiol phosphate (an estradiol ester in polymeric form), among many others, have been developed and introduced for medical use as estrogens. ^{[169] [170] [11] [179]} Estramustine phosphate is also an estradiol ester, but with a nitrogen mustard moiety attached, and is used as a cytostatic antineoplastic agent in the treatment of prostate cancer. ^{[169] [170] [180]} Cloxestradiol acetate and promestriene are ether prodrugs of estradiol that have been introduced for medical use as estrogens as well, although they are little known and rarely used. ^{[169] [170]}

Synthetic derivatives of estradiol used as estrogens include ethinylestradiol, ethinylestradiol sulfonate, mestranol, methylestradiol, moxestrol, and quinestrol, all of which are 17α-substituted estradiol derivatives. ^{[169] [170] [11]} Synthetic derivatives of estradiol used in scientific research include 8β-VE2 and 16α-LE2. ^[181]

• v
• t
• e

Structural properties of selected estradiol esters

Estrogen	Structure	Ester(s)				Relative mol. weight	Relative E2 contentb	log Pc
		Position(s)	Moiet(ies)	Type	Lengtha
Estradiol		–	–	–	–	1.00	1.00	4.0
Estradiol acetate		C3	Ethanoic acid	Straight-chain fatty acid	2	1.15	0.87	4.2
Estradiol benzoate		C3	Benzoic acid	Aromatic fatty acid	– (~4–5)	1.38	0.72	4.7
Estradiol dipropionate		C3, C17β	Propanoic acid (×2)	Straight-chain fatty acid	3 (×2)	1.41	0.71	4.9
Estradiol valerate		C17β	Pentanoic acid	Straight-chain fatty acid	5	1.31	0.76	5.6–6.3
Estradiol benzoate butyrate		C3, C17β	Benzoic acid, butyric acid	Mixed fatty acid	– (~6, 2)	1.64	0.61	6.3
Estradiol cypionate		C17β	Cyclopentylpropanoic acid	Cyclic fatty acid	– (~6)	1.46	0.69	6.9
Estradiol enanthate		C17β	Heptanoic acid	Straight-chain fatty acid	7	1.41	0.71	6.7–7.3
Estradiol dienanthate		C3, C17β	Heptanoic acid (×2)	Straight-chain fatty acid	7 (×2)	1.82	0.55	8.1–10.4
Estradiol undecylate		C17β	Undecanoic acid	Straight-chain fatty acid	11	1.62	0.62	9.2–9.8
Estradiol stearate		C17β	Octadecanoic acid	Straight-chain fatty acid	18	1.98	0.51	12.2–12.4
Estradiol distearate		C3, C17β	Octadecanoic acid (×2)	Straight-chain fatty acid	18 (×2)	2.96	0.34	20.2
Estradiol sulfate		C3	Sulfuric acid	Water-soluble conjugate	–	1.29	0.77	0.3–3.8
Estradiol glucuronide		C17β	Glucuronic acid	Water-soluble conjugate	–	1.65	0.61	2.1–2.7
Estramustine phosphate d		C3, C17β	Normustine, phosphoric acid	Water-soluble conjugate	–	1.91	0.52	2.9–5.0
Polyestradiol phosphate e		C3–C17β	Phosphoric acid	Water-soluble conjugate	–	1.23f	0.81f	2.9g
Footnotes:a = Length of ester in carbon atoms for straight-chain fatty acids or approximate length of ester in carbon atoms for aromatic or cyclic fatty acids. b = Relative estradiol content by weight (i.e., relative estrogenic exposure). c = Experimental or predicted octanol/water partition coefficient (i.e., lipophilicity/hydrophobicity). Retrieved from PubChem, ChemSpider, and DrugBank. d = Also known as estradiol normustine phosphate. e = Polymer of estradiol phosphate (~13 repeat units). f = Relative molecular weight or estradiol content per repeat unit. g = log P of repeat unit (i.e., estradiol phosphate). Sources: See individual articles.

History

See also: Estradiol § History

Estradiol was first discovered and synthesized in 1933 via reduction of estrone. ^[28] Subsequently, estradiol was isolated for the first time in 1935. ^{[27] [182]} It was also originally known as dihydroxyestrin, dihydrofolliculin, or alpha-estradiol. ^{[171] [183]}

Estradiol was first introduced for medical use, in the form of estradiol benzoate, a short-acting ester prodrug of estradiol administered by intramuscular injection in oil solution, under the brand name Progynon B in 1933. ^{[29] [30] [31] [184]} Estradiol itself was also marketed in the 1930s and 1940s in the form of oral tablets and solutions, vaginal suppositories, and topical ointments under a variety of brand names including Dimenformon, Gynoestryl, Ovocyclin, Progynon, and Progynon DH. ^{[185] [171] [186] [183] [187] [188] [189]} Marketed vaginal estradiol suppositories were also used rectally. ^[190] Estradiol dipropionate, another short-acting ester of estradiol in oil solution for use by intramuscular injection, was marketed under the brand name Di-Ovocylin by 1939. ^{[191] [185]} In contrast to estrone, estradiol was never marketed in oil solution for intramuscular injection. ^{[192] [189] [193] [194] [185] [171] [186] [183] [187] [188]} This is attributable to its short duration of action and the availability of longer-acting estradiol esters like estradiol benzoate and estradiol dipropionate. ^{[192] [195]}

Delivery of estrogens by nasal spray was studied in 1929, ^{[184] [196]} and an estradiol nasal spray for local use was marketed by Schering under the brand name Progynon DH Nasal Spray by 1941. ^{[197] [198]} Sublingual administration of estradiol was first described in the early 1940s. ^{[199] [200] [201]} Buccal estradiol tablets were marketed by Schering under the brand name Progynon Buccal Tablets by 1949. ^[202] Estradiol tablets for use by the sublingual route were marketed under the brand name Estradiol Membrettes in 1950, ^{[203] [204] [205] [206]} as well as under the brand name Diogynets by 1952. ^{[207] [208] [209]} Longer-acting esters of estradiol in oil solution like estradiol valerate (Delestrogen, Progynon Depot), estradiol cypionate (Depo-Estradiol), and estradiol undecylate (Delestrec, Progynon Depot 100), as well as the polymeric estradiol ester polyestradiol phosphate in aqueous solution (Estradurin), were developed and introduced for use by intramuscular injection in the 1950s. ^{[170] [169] [210] [211]}

Due to poor absorption and low potency relative to other estrogens, oral estradiol was not widely used as late as the early 1970s. ^[212] Instead, synthetic and animal-derived estrogens like conjugated estrogens, ethinylestradiol, and diethylstilbestrol were typically used by the oral route. ^[212] In 1966, oral estradiol valerate was introduced by Schering for medical use under the brand name Progynova. ^{[32] [33] [213] [214]} Esterification of estradiol, as in estradiol valerate, was believed to improve its metabolic stability with oral administration. ^{[11] [6]} Studies in the 1960s showed that micronization of steroids such as spironolactone and norethisterone acetate improved their absorption and oral potency by several-fold. ^{[215] [216] [217] [218] [219]} In 1972, micronization of estradiol was studied in women and was likewise found to improve the absorption and potency of estradiol by the oral route. ^[212] Subsequently, oral micronized estradiol was introduced for medical use in the United States under the brand name Estrace in 1975. ^{[34] [220]} However, oral micronized estradiol valerate had been introduced by Schering in 1968. ^[221] Oral micronized estradiol and oral estradiol valerate have similar bioavailability and are both now widely used throughout the world. ^{[11] [6]}

After the introduction of oral micronized estradiol, vaginal and intranasal micronized estradiol were evaluated in 1977 and both subsequently introduced. ^{[222] [11]}

The first transdermal estradiol gel, a hydroalcoholic gel known as EstroGel, was initially described in 1980 and was introduced in Europe around 1981. ^[223] Transdermal estradiol gel did not become available in the United States until 2004, when EstroGel was introduced in this country as well. ^[223] A transdermal estradiol emulsion, Estrasorb, was marketed in the United States in 2003 as well. ^[223] One of the earliest reports of transdermal estradiol patches was published in 1983. ^{[223] [224]} Estraderm, a reservoir patch and the first transdermal estradiol patch to be marketed, was introduced in Europe in 1985 and in the United States in 1986. ^{[225] [226]} The first transdermal matrix estradiol patches to be introduced were Climara and Vivelle between 1994 and 1996, and were followed by many others. ^{[223] [227]}

Ethinylestradiol, a synthetic derivative of estradiol, was synthesized from estradiol by Inhoffen and Hohlweg in 1938 and was introduced for oral use by Schering in the United States under the brand name Estinyl in 1943. ^{[228] [229]} Starting in the 1950s, ethinylestradiol became widely used in birth control pills. ^[228] Estradiol-containing birth control pills were initially studied in the 1970s, with the first report published in 1977. ^{[230] [231]} Development of birth control pills containing estradiol was motivated by the thrombotic risks of ethinylestradiol that were uncovered in the 1960s and 1970s. ^{[232] [233] [234] [231]} More than 15 attempts were made at development of an estradiol-containing birth control pill starting in the 1970s, but were unsuccessful due to unacceptable menstrual bleeding patterns. ^[231] Estradiol valerate/cyproterone acetate (Femilar) was introduced for use as a birth control pill in Finland in 1993, but was never marketed elsewhere. ^[235] Subsequently, estradiol valerate/dienogest (Natazia, Qlaira) was marketed as a birth control pill in 2008 ^[236] and estradiol/nomegestrol acetate (Naemis, Zoely) was introduced in 2012. ^[128]

Society and culture

Generic names

Estradiol is the generic name of estradiol in American English and its INN Tooltip INN, USAN Tooltip United States Adopted Name, USP Tooltip United States Pharmacopeia, BAN Tooltip British Approved Name, DCF Tooltip Dénomination Commune Française, and JAN Tooltip Japanese Accepted Name. ^{[237] [170] [169] [238] [239]} Estradiolo is the name of estradiol in Italian and the DCIT Tooltip Denominazione Comune Italiana ^[237] and estradiolum is its name in Latin, whereas its name remains unchanged as estradiol in Spanish, Portuguese, French, and German. ^{[237] [170]} Oestradiol was the former BAN Tooltip British Approved Name of estradiol and its name in British English, ^[238] but the spelling was eventually changed to estradiol. ^[237] When estradiol is provided in its hemihydrate form, its INN Tooltip INN is estradiol hemihydrate. ^[170]

Brand names

See also: List of estrogen esters § Estradiol esters, Combined injectable contraceptive § Available forms, and Estradiol-containing oral contraceptive

Estradiol is marketed under a large number of brand names throughout the world. ^{[170] [237]} Examples of major brand names in which estradiol has been marketed in include Climara, Climen, Dermestril, Divigel, Estrace, Natifa, Estraderm, Estraderm TTS, Estradot, Estreva, Estrimax, Estring, Estrofem, EstroGel, Evorel, Fem7 (or FemSeven), Imvexxy, Menorest, Oesclim, OestroGel, Sandrena, Systen, and Vagifem. ^{[170] [237]} Estradiol valerate is marketed mainly as Progynova and Progynon-Depot, while it is marketed as Delestrogen in the US. ^{[170] [176] [ failed verification ]} Estradiol cypionate is used mainly in the US and is marketed under the brand name Depo-Estradiol. ^{[170] [176] [ failed verification ]} Estradiol acetate is available as Femtrace, Femring, and Menoring. ^{[176] [ failed verification ]}

Estradiol is also widely available in combination with progestogens. ^[237] It is available in combination with norethisterone acetate under the major brand names Activelle, Cliane, Estalis, Eviana, Evorel Conti, Evorel Sequi, Kliogest, Novofem, Sequidot, and Trisequens; with drospirenone as Angeliq; with dydrogesterone as Femoston, Femoston Conti; and with nomegestrol acetate as Zoely. ^[237] Estradiol valerate is available with cyproterone acetate as Climen; with dienogest as Climodien and Qlaira; with norgestrel as Cyclo-Progynova and Progyluton; with levonorgestrel as Klimonorm; with medroxyprogesterone acetate as Divina and Indivina; and with norethisterone enantate as Mesigyna and Mesygest. ^[237] Estradiol cypionate is available with medroxyprogesterone acetate as Cyclo-Provera, Cyclofem, Feminena, Lunelle, and Novafem; ^[16] estradiol enantate with algestone acetophenide as Deladroxate and Topasel; ^{[237] [240]} and estradiol benzoate is marketed with progesterone as Mestrolar and Nomestrol. ^[237]

Estradiol valerate is also widely available in combination with prasterone enantate (DHEA enantate) under the brand name Gynodian Depot. ^[237]

Slang Names

Estradiol has a number of humorous nicknames among the transgender community. Among them are titty skittles, breast mints, femme&m's, antiboyotics, anticistamines, trans-mission fluid, and the Notorious H.R.T. ^[241]

Availability

Estradiol and/or its esters are widely available in countries throughout the world in a variety of formulations. ^{[237] [242] [243] [170] [176] [ failed verification ]}

Shortages of estradiol began around 2022, caused partly by the COVID-19 pandemic disrupting supply and due to increasing demand. In Britain, for example, prescriptions for all hormone replacement therapy drugs more than doubled between 2018 and 2022. The shortage remains as of March 2024. ^{[244] [245] [246]}

United States

See also: List of estrogens available in the United States

Vivelle-Dot, an estradiol patch

As of November 2016 ^[update] , estradiol is available in the United States in the following forms: ^{[176] [ failed verification ]}

• Oral tablets (Femtrace (as estradiol acetate), Gynodiol, Innofem, generics)
• Transdermal patches (Alora, Climara, Esclim, Estraderm, FemPatch, Menostar, Minivelle, Vivelle, Vivelle-Dot, generics)
• Topical gels (Divigel, Elestrin, EstroGel, Sandrena), emulsions (Estrasorb), and sprays (Evamist)
• Vaginal tablets (Vagifem, generics), creams (Estrace), inserts (Imvexxy), and rings (Estring, Femring (as estradiol acetate))
• Oil solution for intramuscular injection (Delestrogen (as estradiol valerate), Depo-Estradiol (as estradiol cypionate))

Oral estradiol valerate (Progynova) and other esters of estradiol that are used by injection like estradiol benzoate, estradiol enantate, and estradiol undecylate all are not marketed in the US. ^{[176] [ failed verification ]} Polyestradiol phosphate (Estradurin) was marketed in the US previously but is no longer available. ^[247]

Estradiol is also available in the US in combination with progestogens for the treatment of menopausal symptoms and as a combined hormonal contraceptive: ^{[176] [ failed verification ]}

• Oral oil-filled capsules with progesterone (Bijuva) ^{[248] [249]}
• Oral tablets with drospirenone (Angeliq) and norethisterone acetate (Activella, Amabelz) and as estradiol valerate with dienogest (Natazia)
• Transdermal patches with levonorgestrel (Climara Pro) and norethisterone acetate (Combipatch)

Estradiol and estradiol esters are also available in custom preparations from compounding pharmacies in the US. ^[250] This includes subcutaneous pellet implants, which are not available in the United States as FDA-approved pharmaceutical drugs. ^[251] In addition, topical creams that contain estradiol are generally regulated as cosmetics rather than as drugs in the US and hence are also sold over-the-counter and may be purchased without a prescription on the Internet. ^[252]

Other countries

Pharmaceutical estradiol subcutaneous pellet implants were formerly available in the United Kingdom and Australia under the brand name Estradiol Implants or Oestradiol Implants (Organon; 25, 50, or 100 mg), but have been discontinued. ^{[170] [253] [254] [255] [256]} However, an estradiol subcutaneous implant with the brand name Meno-Implant (Organon; 20 mg) continues to be available in the Netherlands. ^{[237] [170] [257] [258]} Previously, for instance in the 1970s and 1980s, other subcutaneous estradiol implant products such as Progynon Pellets (Schering; 25 mg) and Estropel Pellets (25 mg; Bartor Pharmacol) were marketed. ^{[259] [260] [261]} It has been said that pharmaceutical estradiol implants have been almost exclusively used in the United Kingdom. ^[262] Subcutaneous estradiol implants are also available as custom compounded products in some countries. ^{[263] [251] [264]}

Economics

Generic oral estradiol tablets are much less expensive than other forms of estradiol such as transdermal gel and patches and vaginal rings. ^[265]

Research

A variety of estradiol-containing combined birth control pills were studied but never marketed. ^[235] In addition, a variety of estradiol-containing combined injectable contraceptives were studied but never marketed. ^{[16] [266] [267] [268] [269]}

Estradiol has been studied in the treatment of postpartum depression and postpartum psychosis. ^{[270] [271] [272] [273] [274]}

Estrogens such as estradiol appear to improve sexual desire and function in women. ^{[275] [276]} However, the available evidence overall does not support the use of estradiol and other estrogens for improving sexual desire and function in women as of 2016. ^[276] An exception is the use of estrogens to treat vaginal atrophy. ^[276]

Estrogen therapy has been proposed as a potential treatment for autism but clinical studies are needed. ^[277]

References

1. Ford SM, Roach SS (7 October 2013). Roach's Introductory Clinical Pharmacology. Lippincott Williams & Wilkins. pp. 525–. ISBN   978-1-4698-3214-2.
2. Hochadel M (1 April 2015). Mosby's Drug Reference for Health Professions. Elsevier Health Sciences. pp. 602–. ISBN   978-0-323-31103-8.
3. "Imvexxy Product information". Health Canada. 25 April 2012. Archived from the original on 6 June 2022. Retrieved 5 June 2022.
4. "Active substance: estradiol (except cream/balm/emulsion for application in female genital area)" (PDF). List of nationally authorised medicinal products. European Medicines Agency. Archived (PDF) from the original on 10 June 2022. Retrieved 10 June 2022.
5. Stanczyk FZ, Archer DF, Bhavnani BR (June 2013). "Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment". Contraception. 87 (6): 706–727. doi:10.1016/j.contraception.2012.12.011. PMID   23375353.
6. Düsterberg B, Nishino Y (December 1982). "Pharmacokinetic and pharmacological features of oestradiol valerate". Maturitas. 4 (4): 315–324. doi:10.1016/0378-5122(82)90064-0. PMID   7169965.
7. Falcone T, Hurd WW (2007). Clinical Reproductive Medicine and Surgery. Elsevier Health Sciences. pp. 22, 362, 388. ISBN   978-0-323-03309-1. Archived from the original on 15 April 2021. Retrieved 27 November 2016.
8. Price TM, Blauer KL, Hansen M, Stanczyk F, Lobo R, Bates GW (March 1997). "Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17 beta-estradiol". Obstetrics and Gynecology. 89 (3): 340–345. doi:10.1016/S0029-7844(96)00513-3. PMID   9052581. S2CID   71641652.
9. Naunton M, Al Hadithy AF, Brouwers JR, Archer DF (2006). "Estradiol gel: review of the pharmacology, pharmacokinetics, efficacy, and safety in menopausal women". Menopause. 13 (3): 517–527. doi:10.1097/01.gme.0000191881.52175.8c. PMID   16735950. S2CID   42748448.
10. Sierra-Ramírez JA, Lara-Ricalde R, Lujan M, Velázquez-Ramírez N, Godínez-Victoria M, Hernádez-Munguía IA, et al. (December 2011). "Comparative pharmacokinetics and pharmacodynamics after subcutaneous and intramuscular administration of medroxyprogesterone acetate (25 mg) and estradiol cypionate (5 mg)". Contraception. 84 (6): 565–570. doi:10.1016/j.contraception.2011.03.014. PMID   22078184.
11. Kuhl H (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID   16112947. S2CID   24616324. Archived (PDF) from the original on 22 August 2016. Retrieved 5 December 2016.
12. Oettel M, Schillinger E (6 December 2012). Estrogens and Antiestrogens I: Physiology and Mechanisms of Action of Estrogens and Antiestrogens. Springer Science & Business Media. pp. 121, 226, 235–237. ISBN   978-3-642-58616-3. Archived from the original on 15 December 2020. Retrieved 5 December 2016.
13. Oettel M, Schillinger E (6 December 2012). Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen. Springer Science & Business Media. pp. 163–178, 235–237, 252–253, 261–276, 538–543. ISBN   978-3-642-60107-1. Archived from the original on 14 September 2020. Retrieved 27 November 2016.
14. Christin-Maitre S (2017). "Use of Hormone Replacement in Females with Endocrine Disorders". Hormone Research in Paediatrics. 87 (4): 215–223. doi: 10.1159/000457125 . PMID   28376481. S2CID   3785166.
15. Christin-Maitre S, Laroche E, Bricaire L (January 2013). "A new contraceptive pill containing 17β-estradiol and nomegestrol acetate". Women's Health. 9 (1): 13–23. doi: 10.2217/whe.12.70 . PMID   23241152. S2CID   31617961.
16. Newton JR, D'arcangues C, Hall PE (1994). "A review of "once-a-month" combined injectable contraceptives". Journal of Obstetrics and Gynaecology. 4 (Suppl 1): S1-34. doi:10.3109/01443619409027641. PMID   12290848.
17. Wesp LM, Deutsch MB (March 2017). "Hormonal and Surgical Treatment Options for Transgender Women and Transfeminine Spectrum Persons". The Psychiatric Clinics of North America. 40 (1): 99–111. doi:10.1016/j.psc.2016.10.006. PMID   28159148.
18. Ali Shah SI (2015). "Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer". South Asian Journal of Cancer. 4 (2): 95–97. doi: 10.4103/2278-330X.155699 . PMC   4418092 . PMID   25992351.
19. Coelingh Bennink HJ, Verhoeven C, Dutman AE, Thijssen J (January 2017). "The use of high-dose estrogens for the treatment of breast cancer". Maturitas. 95: 11–23. doi: 10.1016/j.maturitas.2016.10.010 . PMID   27889048.
20. "Estrace- estradiol tablet". DailyMed. 11 March 2024. Retrieved 17 May 2024.
21. Richard P. Pohanish (2011). Sittig's Handbook of Toxic and Hazardous Chemicals and Carcinogens. William Andrew. pp. 1167–. ISBN   978-1-4377-7869-4. Archived from the original on 6 May 2020. Retrieved 29 June 2018.
22. Cecil RL, Bennett JC, Plum F (1996). Cecil Textbook of Medicine . Saunders. ISBN   978-0-7216-3575-0. Estrogen excess in men causes inhibition of gonadotropin secretion and secondary hypogonadism. Estrogen excess may result from either exogenous administration of estrogens or estrogenic substances (e.g., diethylstilbestrol administration [...]
23. Yang Z, Hu Y, Zhang J, Xu L, Zeng R, Kang D (February 2017). "Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis". Gynecological Endocrinology. 33 (2): 87–92. doi:10.1080/09513590.2016.1248932. PMID   27898258. S2CID   205631264.
24. Lambrinoudaki I (April 2014). "Progestogens in postmenopausal hormone therapy and the risk of breast cancer". Maturitas. 77 (4): 311–317. doi:10.1016/j.maturitas.2014.01.001. PMID   24485796.
25. Stege R, Carlström K, Collste L, Eriksson A, Henriksson P, Pousette A (1988). "Single drug polyestradiol phosphate therapy in prostatic cancer". American Journal of Clinical Oncology. 11 (Suppl 2): S101–S103. doi:10.1097/00000421-198801102-00024. PMID   3242384. S2CID   32650111.
26. Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD (May 2003). "Transdermal estradiol therapy for advanced prostate cancer--forward to the past?". The Journal of Urology. 169 (5): 1735–1737. doi:10.1097/01.ju.0000061024.75334.40. PMID   12686820.
27. Parl FF (2000). Estrogens, Estrogen Receptor and Breast Cancer. IOS Press. pp. 4, 111. ISBN   978-0-9673355-4-4. Archived from the original on 6 May 2020. Retrieved 27 November 2016.
28. Lauritzen C, Studd JW (22 June 2005). Current Management of the Menopause. CRC Press. pp. 44, 95–98, 488. ISBN   978-0-203-48612-2. Archived from the original on 6 May 2020. Retrieved 11 June 2019.
29. Kaufman C (1933). "Die Behandlung der Amenorrhöe mit Hohen Dosen der Ovarialhormone". Klinische Wochenschrift. 12 (40): 1557–1562. doi:10.1007/BF01765673. ISSN   0023-2173. S2CID   25856898.
30. Buschbeck H (2009). "Neue Wege der Hormontherapie in der Gynäkologie" [New ways of hormonal therapy in gynecology]. Deutsche Medizinische Wochenschrift. 60 (11): 389–393. doi:10.1055/s-0028-1129842. ISSN   0012-0472. S2CID   72668930.
31. Biskind MS (1935). "Commercial Glandular Products". Journal of the American Medical Association. 105 (9): 667. doi:10.1001/jama.1935.92760350007009a. ISSN   0002-9955. Progynon-B, Schering Corporation: This is crystalline hydroxyestrin benzoate obtained by hydrogenation of theelin and subsequent conversion to the benzoate. [...] Progynon-B is marketed in ampules containing 1 cc. of a sesame oil solution of hydroxyestrin benzoate of either 2,500, 5,000, 10,000 or 50,000 international units.
32. "Neue Spezialitäten". Klinische Wochenschrift. 44 (23): 1381. 1966. doi:10.1007/BF01747900. ISSN   0023-2173. S2CID   20357182. NEUE SPEZIALITATEN [...] Progynova. 1 Dragee enthält 2 mg Oestradiolvalerinat (Klimakterium). Hersteller: Schering AG, Berlin 65.
33. Dapunt O (September 1967). "[The management of climacteric disorders using estradiol valerate (Progynova)]" [The management of climacteric disorders using estradiol valerate (Progynova)]. Medizinische Klinik (in German). 62 (35): 1356–61 passim. PMID   5593020.
34. "Estrace: FDA-Approved Drugs". Archived from the original on 6 May 2020. Retrieved 27 November 2016.
35. "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
36. "Estradiol Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
37. "First Generic Drug Approvals 2022". U.S. Food and Drug Administration (FDA). 17 October 2022. Retrieved 28 November 2022.
38. "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.
39. "First Generic Drug Approvals 2023". U.S. Food and Drug Administration (FDA). 30 May 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.
40. Notelovitz M, Lenihan JP, McDermott M, Kerber IJ, Nanavati N, Arce J (May 2000). "Initial 17beta-estradiol dose for treating vasomotor symptoms". Obstetrics and Gynecology. 95 (5): 726–731. doi:10.1016/s0029-7844(99)00643-2. PMID   10775738. S2CID   42621608.
41. Wiegratz I, Kuhl H (2007). "Praxis der Hormontherapie in der Peri- und Postmenopause" [Practice of peri- and postmenopausal hormone therapy]. Gynäkologische Endokrinologie. 5 (3): 141–149. doi:10.1007/s10304-007-0194-9. ISSN   1610-2894. S2CID   27130717.
42. Mutschler E, Schäfer-Korting M (2001). Arzneimittelwirkungen (in German) (8 ed.). Stuttgart: Wissenschaftliche Verlagsgesellschaft. pp. 434, 444. ISBN   978-3-8047-1763-3.
43. Whedon JM, KizhakkeVeettil A, Rugo NA, Kieffer KA (January 2017). "Bioidentical Estrogen for Menopausal Depressive Symptoms: A Systematic Review and Meta-Analysis". Journal of Women's Health. 26 (1): 18–28. doi:10.1089/jwh.2015.5628. PMID   27603786.
44. Matthews D, Bath L, Högler W, Mason A, Smyth A, Skae M (October 2017). "Hormone supplementation for pubertal induction in girls" (PDF). Archives of Disease in Childhood. 102 (10): 975–980. doi:10.1136/archdischild-2016-311372. PMID   28446424. S2CID   39539979. Archived (PDF) from the original on 10 March 2020. Retrieved 16 August 2019.
45. Rosenthal L, Burchum J (17 February 2017). Lehne's Pharmacotherapeutics for Advanced Practice Providers - E-Book. Elsevier Health Sciences. pp. 524–. ISBN   978-0-323-44779-9. Archived from the original on 10 June 2022. Retrieved 3 July 2018.
46. World Professional Association for Transgender Health (September 2011), Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People, Seventh Version (PDF), archived from the original (PDF) on 6 January 2016
47. Evans G, Sutton EL (May 2015). "Oral contraception". The Medical Clinics of North America. 99 (3): 479–503. doi:10.1016/j.mcna.2015.01.004. PMID   25841596.
48. Glasier A (2010). "Contraception". In Jameson JL, De Groot LJ (eds.). Endocrinology (6th ed.). Philadelphia: Saunders Elsevier. pp. 2417–2427. ISBN   978-1-4160-5583-9.
49. Lycette JL, Bland LB, Garzotto M, Beer TM (December 2006). "Parenteral estrogens for prostate cancer: can a new route of administration overcome old toxicities?". Clinical Genitourinary Cancer. 5 (3): 198–205. doi:10.3816/CGC.2006.n.037. PMID   17239273.
50. Cox RL, Crawford ED (December 1995). "Estrogens in the treatment of prostate cancer". The Journal of Urology. 154 (6): 1991–1998. doi:10.1016/S0022-5347(01)66670-9. PMID   7500443.
51. Altwein J (1983). "Controversial Aspects of Hormone Manipulation in Prostatic Carcinoma". Cancer of the Prostate and Kidney. NATO Advanced Science Institutes Series. Springer. pp. 305–316. doi:10.1007/978-1-4684-4349-3_38. ISBN   978-1-4684-4351-6.
52. Ockrim JL, Lalani EN, Kakkar AK, Abel PD (August 2005). "Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism". The Journal of Urology. 174 (2): 527–33, discussion 532–3. doi:10.1097/01.ju.0000165567.99142.1f. PMID   16006886.
53. Hong WK, Holland JF (2010). Holland-Frei Cancer Medicine 8. PMPH-USA. pp. 753–. ISBN   978-1-60795-014-1. Archived from the original on 4 May 2020. Retrieved 9 December 2016.
54. Scherr DS, Pitts WR (November 2003). "The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer". The Journal of Urology. 170 (5): 1703–1708. doi:10.1097/01.ju.0000077558.48257.3d. PMID   14532759.
55. Coss CC, Jones A, Parke DN, Narayanan R, Barrett CM, Kearbey JD, et al. (March 2012). "Preclinical characterization of a novel diphenyl benzamide selective ERα agonist for hormone therapy in prostate cancer". Endocrinology. 153 (3): 1070–1081. doi: 10.1210/en.2011-1608 . PMID   22294742.
56. von Schoultz B, Carlström K, Collste L, Eriksson A, Henriksson P, Pousette A, et al. (1989). "Estrogen therapy and liver function--metabolic effects of oral and parenteral administration". The Prostate. 14 (4): 389–395. doi:10.1002/pros.2990140410. PMID   2664738. S2CID   21510744.
57. Ockrim J, Lalani EN, Abel P (October 2006). "Therapy Insight: parenteral estrogen treatment for prostate cancer--a new dawn for an old therapy". Nature Clinical Practice. Oncology. 3 (10): 552–563. doi:10.1038/ncponc0602. PMID   17019433. S2CID   6847203.
58. Wibowo E, Schellhammer P, Wassersug RJ (January 2011). "Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy". The Journal of Urology. 185 (1): 17–23. doi:10.1016/j.juro.2010.08.094. PMID   21074215.
59. Thomas JA, Keenan EJ (6 December 2012). Principles of Endocrine Pharmacology. Springer Science & Business Media. pp. 148–. ISBN   978-1-4684-5036-1.
60. Miller WR, Ingle JN (8 March 2002). Endocrine Therapy in Breast Cancer. CRC Press. pp. 49–52. ISBN   978-0-203-90983-6. Archived from the original on 14 January 2017. Retrieved 9 December 2016.
61. Ellis MJ, Dehdahti F, Kommareddy A, Jamalabadi-Majidi S, Crowder R, Jeffe DB, et al. (2014). "A randomized phase 2 trial of low dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer". Cancer Research. 69 (2 Supplement): 16. doi:10.1158/0008-5472.SABCS-16. ISSN   0008-5472.
62. Palmieri C, Patten DK, Januszewski A, Zucchini G, Howell SJ (January 2014). "Breast cancer: current and future endocrine therapies". Molecular and Cellular Endocrinology. 382 (1): 695–723. doi:10.1016/j.mce.2013.08.001. PMID   23933149. S2CID   3363705.
63. "Estradurin (Polyestradiol Phosphate)". Pharmanovia. Archived from the original on 2 January 2018. Retrieved 29 June 2018.
64. Ostrowski MJ, Jackson AW (1979). "Polyestradiol phosphate: a preliminary evaluation of its effect on breast carcinoma". Cancer Treatment Reports. 63 (11–12): 1803–1807. PMID   393380.
65. Aiman J (6 December 2012). Infertility: Diagnosis and Management. Springer Science & Business Media. pp. 133–134. ISBN   978-1-4613-8265-2.
66. Schattman GL, Esteves S, Agarwal A (12 May 2015). Unexplained Infertility: Pathophysiology, Evaluation and Treatment. Springer. pp. 266–. ISBN   978-1-4939-2140-9.
67. Pinheiro LM, Cândido PD, Moreto TC, Almeida WG, Castro EC (September 2017). "Estradiol use in the luteal phase and its effects on pregnancy rates in IVF cycles with GnRH antagonist: a systematic review". JBRA Assisted Reproduction. 21 (3): 247–250. doi:10.5935/1518-0557.20170046. PMC   5574648 . PMID   28837035.
68. Labhart A (6 December 2012). Clinical Endocrinology: Theory and Practice. Springer Science & Business Media. pp. 512, 696. ISBN   978-3-642-96158-8.
69. Juul A (2001). "The effects of oestrogens on linear bone growth". Human Reproduction Update. 7 (3): 303–313. doi: 10.1093/humupd/7.3.303 . PMID   11392377.
70. Albuquerque EV, Scalco RC, Jorge AA (June 2017). "MANAGEMENT OF ENDOCRINE DISEASE: Diagnostic and therapeutic approach of tall stature". European Journal of Endocrinology. 176 (6): R339–R353. doi: 10.1530/EJE-16-1054 . PMID   28274950.
71. Upners EN, Juul A (November 2016). "Evaluation and phenotypic characteristics of 293 Danish girls with tall stature: effects of oral administration of natural 17β-estradiol". Pediatric Research. 80 (5): 693–701. doi: 10.1038/pr.2016.128 . PMID   27410906. S2CID   24233612.
72. Göretzlehner G, Lauritzen C, Römer T, Rossmanith W (1 January 2012). Praktische Hormontherapie in der Gynäkologie. Walter de Gruyter. pp. 385–. ISBN   978-3-11-024568-4. Archived from the original on 6 October 2021. Retrieved 22 July 2018.
73. Mansel RE, Fodstad O, Jiang WG (14 June 2007). Metastasis of Breast Cancer. Springer Science & Business Media. pp. 217–. ISBN   978-1-4020-5866-0. Archived from the original on 1 December 2016. Retrieved 22 July 2018.
74. Hartmann BW, Laml T, Kirchengast S, Albrecht AE, Huber JC (April 1998). "Hormonal breast augmentation: prognostic relevance of insulin-like growth factor-I". Gynecological Endocrinology. 12 (2): 123–127. doi:10.3109/09513599809024960. PMID   9610425.
75. Lauritzen C (1980). "Hormonkur kann hypoplastischer Mamma aufhelfen" [Hormone therapy can help hypoplastic breasts]. Selecta (in German). 22 (43). Planegg: Selecta-Verlag: 3798–3801. ISSN   0582-4877. OCLC   643821347.
76. Kaiser R, Leidenberger FA (1991). Hormonbehandlung in der gynäkologischen Praxis (6 ed.). Stuttgart, New York: Georg Thieme Verlag. pp. 138–139. ISBN   978-3133574075.
77. Begemann MJ, Dekker CF, van Lunenburg M, Sommer IE (November 2012). "Estrogen augmentation in schizophrenia: a quantitative review of current evidence". Schizophrenia Research. 141 (2–3): 179–184. doi:10.1016/j.schres.2012.08.016. PMID   22998932. S2CID   40584474.
78. Kulkarni J, Gavrilidis E, Wang W, Worsley R, Fitzgerald PB, Gurvich C, et al. (June 2015). "Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age". Molecular Psychiatry. 20 (6): 695–702. doi: 10.1038/mp.2014.33 . PMID   24732671. S2CID   30322760.
79. Brzezinski A, Brzezinski-Sinai NA, Seeman MV (May 2017). "Treating schizophrenia during menopause". Menopause. 24 (5): 582–588. doi:10.1097/GME.0000000000000772. PMID   27824682. S2CID   3452898.
80. McGregor C, Riordan A, Thornton J (October 2017). "Estrogens and the cognitive symptoms of schizophrenia: Possible neuroprotective mechanisms". Frontiers in Neuroendocrinology. 47: 19–33. doi:10.1016/j.yfrne.2017.06.003. PMID   28673758. S2CID   43291520.
81. de Boer J, Prikken M, Lei WU, Begemann M, Sommer I (January 2018). "The effect of raloxifene augmentation in men and women with a schizophrenia spectrum disorder: a systematic review and meta-analysis". npj Schizophrenia. 4 (1): 1. doi:10.1038/s41537-017-0043-3. PMC   5762671 . PMID   29321530.
82. Khan MM (July 2016). "Neurocognitive, Neuroprotective, and Cardiometabolic Effects of Raloxifene: Potential for Improving Therapeutic Outcomes in Schizophrenia". CNS Drugs. 30 (7): 589–601. doi:10.1007/s40263-016-0343-6. PMID   27193386. S2CID   22284610.
83. Owens SJ, Murphy CE, Purves-Tyson TD, Weickert TW, Shannon Weickert C (February 2018). "Considering the role of adolescent sex steroids in schizophrenia". Journal of Neuroendocrinology. 30 (2): e12538. doi:10.1111/jne.12538. hdl: 1959.4/unsworks_49994 . PMID   28941299. S2CID   3391650.
84. Guay DR (January 2009). "Drug treatment of paraphilic and nonparaphilic sexual disorders". Clinical Therapeutics. 31 (1): 1–31. doi:10.1016/j.clinthera.2009.01.009. PMID   19243704.
85. Morgan HG, Morgan MH (1984). Aids to Psychiatry . Churchill Livingstone. p.  75. ISBN   978-0-443-02613-3. Treatment of sexual offenders. Hormone therapy. [...] Oestrogens may cause breast hypertrophy, testicular atrophy, osteoporosis (oral ethinyl oestradiol 0.01-0.05 mg/day causes least nausea). Depot preparation: oestradiol [undecyleate] 50-100mg once every 3–4 weeks. Benperidol or butyrophenone and the antiandrogen cyproterone acetate also used.
86. Chatz TL (June 1972). "Recognizing and Treating Dangerous Sex Offenders". International Journal of Offender Therapy and Comparative Criminology. 16 (2): 109–115. doi:10.1177/0306624X7201600202. eISSN   1552-6933. ISSN   0306-624X. S2CID   74365268.
87. "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Retrieved 26 July 2018.
88. Lobo RA (5 June 2007). Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. Academic Press. pp. 177, 217–226, 770–771. ISBN   978-0-08-055309-2.
89. Falcone T, Hurd WW (14 June 2017). Clinical Reproductive Medicine and Surgery: A Practical Guide. Springer. pp. 179–. ISBN   978-3-319-52210-4.
90. Becker KL (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 889, 1059–1060, 2153. ISBN   978-0-7817-1750-2.
91. Kleemann A, Engel J, Kutscher B, Reichert D (14 May 2014). Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs. Thieme. pp. 1167–1174. ISBN   978-3-13-179525-0.
92. Muller (19 June 1998). European Drug Index: European Drug Registrations, Fourth Edition. CRC Press. pp. 276, 454–455, 566–567. ISBN   978-3-7692-2114-5.
93. Krishna UR, Sheriar NK (1996). Menopause. Orient Blackswan. pp. 70–. ISBN   978-81-250-0910-8.
94. "NNR: Products Recently Accepted by the A. M. A. Council on Pharmacy and Chemistry". Journal of the American Pharmaceutical Association (Practical Pharmacy ed.). 10 (11): 692–694. 1949. doi:10.1016/S0095-9561(16)31995-8. ISSN   0095-9561.
95. "AERODIOL (Oestradiol hemihydrate 150 micrograms/actuation)" (PDF). Servier Laboratories (Aust) Pty Ltd.
96. "Estradiol". Drugs.com.
97. Sahin FK, Koken G, Cosar E, Arioz DT, Degirmenci B, Albayrak R, et al. (2008). "Effect of Aerodiol administration on ocular arteries in postmenopausal women". Gynecol. Endocrinol. 24 (4): 173–7. doi:10.1080/09513590701807431. PMID   18382901. 300 μg 17β-estradiol (Aerodiol®; Servier, Chambrayles-Tours, France) was administered via the nasal route by a gynecologist. This product is unavailable after March 31, 2007 because its manufacturing and marketing are being discontinued.
98. Plouffe Jr L, Ravnikar VA, Speroff L, Watts NB (6 December 2012). Comprehensive Management of Menopause. Springer Science & Business Media. pp. 271–. ISBN   978-1-4612-4330-4.
99. Hospital Formulary and Compendium of Useful Information. University of California Press. 1952. pp. 49–. GGKEY:2UAAZRZ5LN0.
100. Leidenberger FA (17 April 2013). Klinische Endokrinologie für Frauenärzte. Springer-Verlag. pp. 527–. ISBN   978-3-662-08110-5.
101. Lemke TL, Williams DA (24 January 2012). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 1419–. ISBN   978-1-60913-345-0. Archived from the original on 10 June 2022. Retrieved 29 June 2018.
102. Mikkola A, Ruutu M, Aro J, Rannikko S, Salo J (1999). "The role of parenteral polyestradiol phosphate in the treatment of advanced prostatic cancer on the threshold of the new millennium". Annales Chirurgiae et Gynaecologiae. 88 (1): 18–21. PMID   10230677.
103. Lauritzen C (September 1990). "Clinical use of oestrogens and progestogens". Maturitas. 12 (3): 199–214. doi:10.1016/0378-5122(90)90004-P. PMID   2215269.
104. Laurtizen C (2001). "Hormone Substitution Before, During and After Menopause" (PDF). In Fisch FH (ed.). Menopause – Andropause: Hormone Replacement Therapy Through the Ages. Krause & Pachernegg: Gablitz. pp. 67–88. ISBN   978-3-901299-34-6. Archived (PDF) from the original on 10 May 2018. Retrieved 11 June 2019.
105. Midwinter A (1976). "Contraindications to estrogen therapy and management of the menopausal syndrome in these cases". In Campbell S (ed.). The Management of the Menopause & Post-Menopausal Years: The Proceedings of the International Symposium held in London 24–26 November 1975 Arranged by the Institute of Obstetrics and Gynaecology, The University of London. MTP Press Limited. pp. 377–382. doi:10.1007/978-94-011-6165-7_33. ISBN   978-94-011-6167-1.
106. "Estring- estradiol ring". DailyMed. 18 September 2023. Retrieved 17 May 2024.
107. "Estring- estradiol system". DailyMed. 27 February 2024. Retrieved 17 May 2024.
108. Rovinski D, Ramos RB, Fighera TM, Casanova GK, Spritzer PM (August 2018). "Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis". Thrombosis Research. 168: 83–95. doi:10.1016/j.thromres.2018.06.014. PMID   29936403. S2CID   49421543.
109. Scarabin PY (August 2018). "Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis". Climacteric. 21 (4): 341–345. doi:10.1080/13697137.2018.1446931. PMID   29570359. S2CID   4229701.
110. Vinogradova Y, Coupland C, Hippisley-Cox J (January 2019). "Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases". BMJ. 364: k4810. doi:10.1136/bmj.k4810. PMC   6326068 . PMID   30626577.
111. Fruzzetti F, Cagnacci A (2018). "Venous thrombosis and hormonal contraception: what's new with estradiol-based hormonal contraceptives?". Open Access Journal of Contraception. 9: 75–79. doi: 10.2147/OAJC.S179673 . PMC   6239102 . PMID   30519125.
112. Roach RE, Lijfering WM, Helmerhorst FM, Cannegieter SC, Rosendaal FR, van Hylckama Vlieg A (January 2013). "The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy". Journal of Thrombosis and Haemostasis. 11 (1): 124–131. doi: 10.1111/jth.12060 . PMID   23136837. S2CID   22306721.
113. Gialeraki A, Valsami S, Pittaras T, Panayiotakopoulos G, Politou M (March 2018). "Oral Contraceptives and HRT Risk of Thrombosis". Clinical and Applied Thrombosis/Hemostasis. 24 (2): 217–225. doi:10.1177/1076029616683802. PMC   6714678 . PMID   28049361.
114. Scarabin PY (December 2014). "Hormones and venous thromboembolism among postmenopausal women". Climacteric. 17 (Suppl 2): 34–37. doi:10.3109/13697137.2014.956717. PMID   25223916. S2CID   5084606.
115. Olié V, Canonico M, Scarabin PY (February 2011). "Postmenopausal hormone therapy and venous thromboembolism". Thrombosis Research. 127 (Suppl 3): S26–S29. doi:10.1016/S0049-3848(11)70008-1. PMID   21262434.
116. Bińkowska M (October 2014). "Menopausal hormone therapy and venous thromboembolism". Przeglad Menopauzalny = Menopause Review. 13 (5): 267–272. doi:10.5114/pm.2014.46468. PMC   4520375 . PMID   26327865.
117. Beyer-Westendorf J, Bauersachs R, Hach-Wunderle V, Zotz RB, Rott H (October 2018). "Sex hormones and venous thromboembolism - from contraception to hormone replacement therapy". VASA. Zeitschrift für Gefässkrankheiten. 47 (6): 441–450. doi:10.1024/0301-1526/a000726. PMID   30008249. S2CID   51628832.
118. Phillips I, Shah SI, Duong T, Abel P, Langley RE (2014). "Androgen Deprivation Therapy and the Re-emergence of Parenteral Estrogen in Prostate Cancer". Oncology & Hematology Review. 10 (1): 42–47. doi:10.17925/ohr.2014.10.1.42. PMC   4052190 . PMID   24932461.
119. Kohli M (January 2006). "Phase II study of transdermal estradiol in androgen-independent prostate carcinoma". Cancer. 106 (1): 234–5, author reply 235. doi: 10.1002/cncr.21528 . PMID   16284988. S2CID   11047031.
120. Horský J, Presl J (1981). "Hormonal Treatment of Disorders of the Menstrual Cycle". In J. Horsky, J. Presl (eds.). Ovarian Function and its Disorders: Diagnosis and Therapy. Developments in Obstetrics and Gynecology. Springer Science & Business Media. pp. 309–332. doi:10.1007/978-94-009-8195-9_11. ISBN   978-94-009-8195-9. Archived from the original on 18 June 2020. Retrieved 26 December 2019.
121. Connors JM, Middeldorp S (November 2019). "Transgender patients and the role of the coagulation clinician". Journal of Thrombosis and Haemostasis. 17 (11): 1790–1797. doi:10.1111/jth.14626. PMID   31465627. S2CID   201673648.
122. Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, et al. (November 2015). "Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline". The Journal of Clinical Endocrinology and Metabolism. 100 (11): 3975–4011. doi: 10.1210/jc.2015-2236 . PMID   26444994.
123. Smith NL, Blondon M, Wiggins KL, Harrington LB, van Hylckama Vlieg A, Floyd JS, et al. (January 2014). "Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens". JAMA Internal Medicine. 174 (1): 25–31. doi:10.1001/jamainternmed.2013.11074. PMC   4636198 . PMID   24081194.
124. Goldstein Z, Khan M, Reisman T, Safer JD (2019). "Managing the risk of venous thromboembolism in transgender adults undergoing hormone therapy". Journal of Blood Medicine. 10: 209–216. doi: 10.2147/JBM.S166780 . PMC   6628137 . PMID   31372078.
125. Davey DA (October 2018). "Menopausal hormone therapy: a better and safer future". Climacteric. 21 (5): 454–461. doi:10.1080/13697137.2018.1439915. PMID   29526116. S2CID   3850275.
126. Bateson D, Butcher BE, Donovan C, Farrell L, Kovacs G, Mezzini T, et al. (2016). "Risk of venous thromboembolism in women taking the combined oral contraceptive: A systematic review and meta-analysis". Australian Family Physician. 45 (1): 59–64. PMID   27051991. Archived from the original on 8 April 2021. Retrieved 26 December 2019.
127. "Updated information about the risk of blood clots in women taking birth control pills containing drospirenone". FDA Drug Safety Communication. Archived from the original on 27 April 2019. Retrieved 15 January 2022.
128. Grandi G, Facchinetti F, Bitzer J (August 2017). "Estradiol in hormonal contraception: real evolution or just same old wine in a new bottle?". The European Journal of Contraception & Reproductive Health Care. 22 (4): 245–246. doi: 10.1080/13625187.2017.1372571 . hdl: 11380/1153791 . PMID   28902531. S2CID   13776462.
129. Khan J, Schmidt RL, Spittal MJ, Goldstein Z, Smock KJ, Greene DN (January 2019). "Venous Thrombotic Risk in Transgender Women Undergoing Estrogen Therapy: A Systematic Review and Metaanalysis". Clinical Chemistry. 65 (1): 57–66. doi: 10.1373/clinchem.2018.288316 . hdl: 11343/240661 . PMID   30602475.
130. L'hermite M, Simoncini T, Fuller S, Genazzani AR (2008). "Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review". Maturitas. 60 (3–4): 185–201. doi:10.1016/j.maturitas.2008.07.007. PMID   18775609.
131. Holtorf K (January 2009). "The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?". Postgraduate Medicine. 121 (1): 73–85. doi:10.3810/pgm.2009.01.1949. PMID   19179815. S2CID   2060730.
132. Conaway E (March 2011). "Bioidentical hormones: an evidence-based review for primary care providers". The Journal of the American Osteopathic Association. 111 (3): 153–164. PMID   21464264. Archived from the original on 29 June 2018. Retrieved 29 June 2018.
133. Simon JA (April 2012). "What's new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone". Climacteric. 15 (Suppl 1): 3–10. doi:10.3109/13697137.2012.669332. PMID   22432810. S2CID   27797540.
134. Mueck AO (April 2012). "Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone". Climacteric. 15 (Suppl 1): 11–17. doi:10.3109/13697137.2012.669624. PMID   22432811. S2CID   8100346.
135. L'Hermite M (August 2013). "HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT". Climacteric. 16 (Suppl 1): 44–53. doi:10.3109/13697137.2013.808563. PMID   23848491. S2CID   20401584.
136. Simon JA (July 2014). "What if the Women's Health Initiative had used transdermal estradiol and oral progesterone instead?". Menopause. 21 (7): 769–783. doi:10.1097/GME.0000000000000169. PMID   24398406. S2CID   30292136.
137. L'Hermite M (August 2017). "Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal". Climacteric. 20 (4): 331–338. doi:10.1080/13697137.2017.1291607. PMID   28301216. S2CID   4771048.
138. Becker KL (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 889, 1059–1060, 2153. ISBN   978-0-7817-1750-2. Archived from the original on 22 February 2022. Retrieved 3 July 2018.
139. "Estradiol" (PDF). Abbott Laboratories. November 2009. Archived from the original (PDF) on 27 November 2021.
140. Smith R (1 January 2001). The Endocrinology of Parturition: Basic Science and Clinical Application. Karger Medical and Scientific Publishers. pp. 89–. ISBN   978-3-8055-7195-1.
141. Song CS, Kappas A (1968). The influence estrogens, progestins, and pregnancy on the liver. Vitamins & Hormones. Vol. 26. Academic Press. pp. 147–195. doi:10.1016/s0083-6729(08)60754-2. ISBN   9780127098265. PMID   4890101.
142. Mueller MN, Kappas A (October 1964). "Estrogen Pharmacology. I. The Influence of Estradiol and Estriol on Hepatic Disposal of Sulfobromophthalein (BSP) in Man". The Journal of Clinical Investigation. 43 (10): 1905–1914. doi:10.1172/JCI105064. PMC   289635 . PMID   14236214.
143. Cheng ZN, Shu Y, Liu ZQ, Wang LS, Ou-Yang DS, Zhou HH (February 2001). "Role of cytochrome P450 in estradiol metabolism in vitro". Acta Pharmacologica Sinica. 22 (2): 148–154. PMID   11741520.
144. Schubert W, Cullberg G, Edgar B, Hedner T (December 1994). "Inhibition of 17 beta-estradiol metabolism by grapefruit juice in ovariectomized women". Maturitas. 20 (2–3): 155–163. doi:10.1016/0378-5122(94)90012-4. PMID   7715468.
145. Hormones, Brain and Behavior. Elsevier. 18 June 2002. pp. 759–761. ISBN   978-0-08-053415-2. Archived from the original on 10 June 2022. Retrieved 23 July 2018.
146. Ginsburg ES, Mello NK, Mendelson JH, Barbieri RL, Teoh SK, Rothman M, et al. (December 1996). "Effects of alcohol ingestion on estrogens in postmenopausal women". JAMA. 276 (21): 1747–1751. doi:10.1001/jama.1996.03540210055034. PMID   8940324.
147. Sarkola T, Mäkisalo H, Fukunaga T, Eriksson CJ (June 1999). "Acute effect of alcohol on estradiol, estrone, progesterone, prolactin, cortisol, and luteinizing hormone in premenopausal women" (PDF). Alcoholism: Clinical and Experimental Research. 23 (6): 976–982. doi:10.1111/j.1530-0277.1999.tb04215.x. PMID   10397281. Archived from the original (PDF) on 10 June 2022. Retrieved 29 July 2018.
148. Leinung MC, Feustel PJ, Joseph J (2018). "Hormonal Treatment of Transgender Women with Oral Estradiol". Transgender Health. 3 (1): 74–81. doi:10.1089/trgh.2017.0035. PMC   5944393 . PMID   29756046.
149. Soltysik K, Czekaj P (April 2013). "Membrane estrogen receptors - is it an alternative way of estrogen action?". Journal of Physiology and Pharmacology. 64 (2): 129–142. PMID   23756388.
150. Prossnitz ER, Barton M (May 2014). "Estrogen biology: new insights into GPER function and clinical opportunities". Molecular and Cellular Endocrinology. 389 (1–2): 71–83. doi:10.1016/j.mce.2014.02.002. PMC   4040308 . PMID   24530924.
151. Ojasoo T, Raynaud JP (November 1978). "Unique steroid congeners for receptor studies". Cancer Research. 38 (11 Pt 2): 4186–4198. PMID   359134. Archived from the original on 27 November 2020. Retrieved 28 March 2018.
152. Ojasoo T, Delettré J, Mornon JP, Turpin-VanDycke C, Raynaud JP (1987). "Towards the mapping of the progesterone and androgen receptors". Journal of Steroid Biochemistry. 27 (1–3): 255–269. doi:10.1016/0022-4731(87)90317-7. PMID   3695484.
153. Raynaud JP, Bouton MM, Moguilewsky M, Ojasoo T, Philibert D, Beck G, et al. (January 1980). "Steroid hormone receptors and pharmacology". Journal of Steroid Biochemistry. 12: 143–157. doi:10.1016/0022-4731(80)90264-2. PMID   7421203.
154. Labhart A (6 December 2012). Clinical Endocrinology: Theory and Practice. Springer Science & Business Media. pp. 548–. ISBN   978-3-642-96158-8. Archived from the original on 3 January 2020. Retrieved 11 November 2018.
155. Dietrich JE (18 June 2014). Female Puberty: A Comprehensive Guide for Clinicians. Springer. pp. 53–. ISBN   978-1-4939-0912-4. Archived from the original on 4 May 2020. Retrieved 9 December 2016.
156. Thornhill R, Gangestad SW (25 September 2008). The Evolutionary Biology of Human Female Sexuality. Oxford University Press. pp. 145–. ISBN   978-0-19-988770-5. Archived from the original on 4 May 2020. Retrieved 9 December 2016.
157. Raine-Fenning NJ, Brincat MP, Muscat-Baron Y (2003). "Skin aging and menopause : implications for treatment". American Journal of Clinical Dermatology. 4 (6): 371–378. doi:10.2165/00128071-200304060-00001. PMID   12762829. S2CID   20392538.
158. Hayward C (31 July 2003). Gender Differences at Puberty. Cambridge University Press. pp. 22–. ISBN   978-0-521-00165-6. Archived from the original on 4 May 2020. Retrieved 9 December 2016.
159. Melmed S, Polonsky KS, Larsen PR, Kronenberg HM (11 November 2015). Williams Textbook of Endocrinology. Elsevier Health Sciences. pp. 1105–. ISBN   978-0-323-34157-8. Archived from the original on 4 May 2020. Retrieved 9 December 2016.
160. Jones RE, Lopez KH (28 September 2013). Human Reproductive Biology. Academic Press. pp. 19–. ISBN   978-0-12-382185-0.
161. Sloane E (2002). Biology of Women. Cengage Learning. pp. 496–. ISBN   978-0-7668-1142-3. Archived from the original on 4 May 2020. Retrieved 9 December 2016.
162. King TL, Brucker MC (25 October 2010). Pharmacology for Women's Health. Jones & Bartlett Learning. pp. 1022–. ISBN   978-0-7637-5329-0.
163. Lobo RA (5 June 2007). Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. Academic Press. pp. 177, 217–226, 770–771. ISBN   978-0-08-055309-2. Archived from the original on 4 May 2020. Retrieved 9 December 2016.
164. Warshawsky D, Landolph Jr JR (31 October 2005). Molecular Carcinogenesis and the Molecular Biology of Human Cancer. CRC Press. pp. 457–. ISBN   978-0-203-50343-0. Archived from the original on 4 May 2020. Retrieved 9 December 2016.
165. Notelovitz M, van Keep PA (6 December 2012). The Climacteric in Perspective: Proceedings of the Fourth International Congress on the Menopause, held at Lake Buena Vista, Florida, October 28–November 2, 1984. Springer Science & Business Media. pp. 397, 399. ISBN   978-94-009-4145-8. Archived from the original on 15 December 2020. Retrieved 27 November 2016. [...] following the menopause, circulating estradiol levels decrease from a premenopausal mean of 120 pg/ml to only 13 pg/ml.
166. Christian C, von Schoultz B (15 March 1994). Hormone Replacement Therapy: Standardized or Individually Adapted Doses?. CRC Press. pp. 9–16, 60. ISBN   978-1-85070-545-1. Archived from the original on 15 December 2020. Retrieved 23 July 2018. The mean integrated estradiol level during a full 28-day normal cycle is around 80 pg/ml.
167. Müller EE, MacLeod RM (6 December 2012). Neuroendocrine Perspectives. Springer Science & Business Media. pp. 121–. ISBN   978-1-4612-3554-5. Archived from the original on 15 December 2020. Retrieved 27 November 2016. [...] [premenopausal] mean [estradiol] concentration of 150 pg/ml [...]
168. Rizk BR, Sallam HN (15 June 2012). Clinical Infertility and In Vitro Fertilization. JP Medical Ltd. pp. 11–. ISBN   978-93-5025-095-2. Archived from the original on 10 June 2022. Retrieved 3 July 2018.
169. Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 897–. ISBN   978-1-4757-2085-3.
170. Index Nominum 2000: International Drug Directory. Taylor & Francis US. 2000. pp. 404–406. ISBN   978-3-88763-075-1. Archived from the original on 7 June 2021. Retrieved 13 September 2012.
171. Fluhmann CF (November 1938). "Estrogenic Hormones: Their Clinical Usage". California and Western Medicine. 49 (5): 362–366. PMC   1659459 . PMID   18744783.
172. Givens JR, Anderson GD (1981). Endocrinology of Pregnancy: Based on the Proceedings of the Fifth Annual Symposium on Gynecologic Endocrinology, Held March 3-5, 1980 at the University of Tennessee, Memphis, Tennessee. Year Book Medical Publishers. p. 158. ISBN   978-0-8151-3529-6. Archived from the original on 10 June 2022. Retrieved 3 July 2018. Estetrol (E4) is an estrogen with four hydroxyl groups. More specifically, E4, is 15α-hydroxyestriol.
173. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, World Health Organization, International Agency for Research On Cancer (2007). Combined Estrogen-Progestogen Contraceptives and Combined Estrogen-Progestogen Menopausal Therapy. World Health Organization. p. 384. ISBN   978-92-832-1291-1. Archived from the original on 6 June 2013. Retrieved 13 September 2012.
174. Desai A, Lee M (7 May 2007). Gibaldi's Drug Delivery Systems in Pharmaceutical Care. ASHP. p. 337. ISBN   978-1-58528-136-7. Archived from the original on 8 June 2013. Retrieved 13 September 2012.
175. Wang-Cheng R, Neuner JM, Barnabei VM (2007). Menopause. ACP Press. pp. 91–. ISBN   978-1-930513-83-9. Archived from the original on 10 June 2016. Retrieved 27 November 2016.
176. "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Archived from the original on 4 November 2016. Retrieved 26 July 2018.
177. Lee M, Desai A (2007). Gibaldi's Drug Delivery Systems in Pharmaceutical Care. ASHP. pp. 336–. ISBN   978-1-58528-136-7. Archived from the original on 10 June 2022. Retrieved 22 July 2018.
178. Nursing2013 Drug Handbook. Lippincott Williams & Wilkins. 2012. pp. 528–. ISBN   978-1-4511-5023-0. Archived from the original on 10 June 2022. Retrieved 22 July 2018.
179. Vermeulen A (1975). "Longacting steroid preparations". Acta Clinica Belgica. 30 (1): 48–55. doi:10.1080/17843286.1975.11716973. PMID   1231448.
180. Ravery V, Fizazi K, Oudard S, Drouet L, Eymard JC, Culine S, et al. (December 2011). "The use of estramustine phosphate in the modern management of advanced prostate cancer". BJU International. 108 (11): 1782–1786. doi: 10.1111/j.1464-410X.2011.10201.x . PMID   21756277. S2CID   33456591.
181. Vaudry H, Kah O (25 January 2018). Trends in Comparative Endocrinology and Neurobiology. Frontiers Media SA. pp. 115–. ISBN   978-2-88945-399-3. Archived from the original on 10 June 2022. Retrieved 3 July 2018.
182. Shoupe D, Haseltine FP (6 December 2012). Contraception. Springer Science & Business Media. pp. 2–. ISBN   978-1-4612-2730-4.
183. Reilly WA (November 1941). "Estrogens: Their Use in Pediatrics". California and Western Medicine. 55 (5): 237–239. PMC   1634235 . PMID   18746057.
184. Novak E (1935). "The Therapeutic Use of Estrogenic Substances". JAMA: The Journal of the American Medical Association. 104 (20): 1815. doi:10.1001/jama.1935.92760200002012. ISSN   0098-7484. Progynon B (Schering), in 1 cc. ampules, of 10,000 or 50,000 international units of hydroxyestrin benzoate in sesame oil.
185. Greene RR (1941). "Endocrine Therapy for Gynecologic Disorders". Medical Clinics of North America. 25 (1): 155–168. doi:10.1016/S0025-7125(16)36624-X. ISSN   0025-7125.
186. Johnstone RW (November 1936). "Sex Hormone Therapy in Gynæcology". Edinburgh Medical Journal. 43 (11): 680–695. PMC   5303355 . PMID   29648134.
187. Fluhmann CF (1944). "Clinical use of extracts from the ovaries". Journal of the American Medical Association. 125 (1): 1. doi:10.1001/jama.1944.02850190003001. ISSN   0002-9955.
188. Macpherson AI (June 1940). "The Use of Œstrogens in Obstetrics and Gynæcology". Edinburgh Medical Journal. 47 (6): 406–424. PMC   5306594 . PMID   29646930.
189. "Nomenclature of Endocrine Preparations". Journal of the American Medical Association. 123 (6): 351. 1943. doi:10.1001/jama.1943.02840410033009. ISSN   0002-9955.
190. Freed SC (1941). "Present Status of Commercial Endocrine Preparations". JAMA: The Journal of the American Medical Association. 117 (14): 1175. doi:10.1001/jama.1941.72820400003010. ISSN   0098-7484.
191. Dorr EM, Greene RR (1939). "Treatment of the menopause with estradiol dipropionate". American Journal of Obstetrics and Gynecology. 38 (3): 458–464. doi:10.1016/S0002-9378(39)90763-5. ISSN   0002-9378.
192. Cantor EB (September 1956). "A survey of estrogens". Postgraduate Medicine. 20 (3): 224–231. doi:10.1080/00325481.1956.11691266. PMID   13359169.
193. Jones GF (November 1949). "Physiology and management of the climacteric". California Medicine. 71 (5): 345–348. PMC   1520053 . PMID   15390574.
194. "NNR: Products Recently Accepted by the A. M. A. Council on Pharmacy and Chemistry". Journal of the American Pharmaceutical Association (Practical Pharmacy Ed.). 10 (11): 692–694. 1949. doi:10.1016/S0095-9561(16)31995-8. ISSN   0095-9561.
195. Reifenstein EC (1944). "Endocrinology: A Synopsis of Normal and Pathologic Physiology, Diagnostic Procedures, and Therapy". Medical Clinics of North America. 28 (5): 1232–1276. doi:10.1016/S0025-7125(16)36180-6. ISSN   0025-7125.
196. Pratt JP (1932). "Ovarian Therapy". Endocrinology. 16 (1): 45–51. doi:10.1210/endo-16-1-45. ISSN   0013-7227.
197. Medical Research Division (1941). Female Sex Hormone Therapy, Part One: The Follicular Hormone: A Clinical Guide. Schering Corporation. pp. 15, 50, 56. Archived from the original on 10 June 2022. Retrieved 31 December 2019. Progynon-DH is α-estradiol, the follicular hormone,1,2,3,4,9 supplied in a variety of preparations suitable for oral and local use, including tablets, solution, ointment, suppositories, and nasal spray. [...] PROGYNON-DH Nasal Spray has been prepared especially for use in [the treatment of atrophic rhinitis], the hormone being administered by atomizer twice a day following the usual irrigation. [...] Progynon-DH Nasal Spray, α-estradiol in oil, prepared for use in the treatment of atrophic rhinitis, otosclerosis, and kindred disorders; in bottle with atomizer, the solution containing 4800 R.U. (0.4 mg.) in 30 cc.
198. Howard ME (1949). Modern Drug Encyclopedia and Therapeutic Index. Drug Publications. p. 696. Archived from the original on 7 June 2020. Retrieved 31 December 2019.
199. Walton RP (1944). "Sublingual Administration of Drugs". Journal of the American Medical Association. 124 (3): 138. doi:10.1001/jama.1944.02850030006002. ISSN   0002-9955.
200. Corner GW (1944). "The Absorption of Steroid Hormones from the Oral Mucous Membranes, with Special Reference to the Sublingual Administration of Progesterone". American Journal of Obstetrics and Gynecology. 47 (5): 670–677. doi:10.1016/S0002-9378(16)40321-2. ISSN   0002-9378.
201. Lisser H, Gordan GS, Aird RB, Arrick MS, Craig LS, Escamilla RF, et al. (November 1950). "Sublingual or buccal administration of steroidal hormones". Postgraduate Medicine. 8 (5): 393–400. doi:10.1080/00325481.1950.11694030. PMID   14780947.
202. "New Prescription Products". Journal of the American Pharmaceutical Association (Practical Pharmacy Ed.). 10 (4): 198–206. 1949. doi:10.1016/S0095-9561(16)31795-9. ISSN   0095-9561.
203. Oil, Paint and Drug Reporter. April 1950. Archived from the original on 10 June 2022. Retrieved 12 December 2019. Trade Briefs Wyeth, Inc., Philadelphia, has commenced marketing "Estradiol Membrettes, 0.25 mg." as an addition to its hormone line.
204. American Professional Pharmacist. American Professional Pharmacist, Incorporated. 1950. p. 647. Archived from the original on 10 June 2022. Retrieved 12 December 2019.
205. Medical Times. Romaine Pierson Pub. 1950. p. 248. Archived from the original on 10 June 2022. Retrieved 12 December 2019.
206. Welsh AL (1951). Dermatological Formulary: A Guide for Medical Students and Resident Physicians in Dermatology. Educational Publishers. p. 155. Archived from the original on 29 August 2021. Retrieved 12 December 2019.
207. Omaha Midwest Clinical Society (1952). Journal. DIOGYNETS*. Estradiol, U.S.P., Transmucosal Tablets 0.125 mg., 0.25 mg. and 1.0 mg.
208. General Practitioner. American Academy of General Practice. April 1954. pp. 168–170. Archived from the original on 10 June 2022. Retrieved 12 December 2019. Diogynets* [...] * brand of estradiol transmucosal tablets, scored: 0.125 mg., 0.25 mg. and 1.0 mg., bottles of 50 and 100.
209. Allan William Spence (1953). Clinical Endocrinology. Cassell. p. 547. Archived from the original on 10 June 2022. Retrieved 15 December 2019.
210. William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia. Elsevier. ISBN   978-0-8155-1856-3.
211. Oriowo MA, Landgren BM, Stenström B, Diczfalusy E (April 1980). "A comparison of the pharmacokinetic properties of three estradiol esters". Contraception. 21 (4): 415–424. doi:10.1016/s0010-7824(80)80018-7. PMID   7389356.
212. Martin PL, Burnier AM, Greaney MO (May 1972). "Oral menopausal therapy using 17- micronized estradiol. A preliminary study of effectiveness, tolerance and patient preference". Obstetrics and Gynecology. 39 (5): 771–774. PMID   5023261 . Retrieved 1 December 2019.
213. Velikay L (March 1968). "[The peroral treatment of the climacteric syndrome with estradiol valerate]" [The peroral treatment of the climacteric syndrome with estradiol valerate]. Wiener Klinische Wochenschrift (in German). 80 (12): 229–233. PMID   5728263.
214. Koed J (May 1972). "[Therapy of climacteric deficiency symptoms using progynova]" [Therapy of climacteric deficiency symptoms using Progynova]. Die Medizinische Welt (in German). 23 (22): 834–836. PMID   5045321.
215. Dorfman RI (5 December 2016). Steroidal Activity in Experimental Animals and Man. Elsevier Science. pp. 392–. ISBN   978-1-4832-7299-3. Archived from the original on 18 August 2020. Retrieved 15 December 2019.
216. Horsky J, Presl J (6 December 2012). Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 313–. ISBN   978-94-009-8195-9. Archived from the original on 21 October 2021. Retrieved 8 December 2019.
217. Brotherton J (1976). Sex Hormone Pharmacology. Academic Press. p. 34. ISBN   978-0-12-137250-7.
218. Gibian H, Kopp R, Kramer M, Neumann F, Richter H (1968). "Effect of particle size on biological activity of norethisterone acetate". Acta Physiologica Latino Americana. 18 (4): 323–326. PMID   5753386.
219. He CH, Shi YE, Liao DL, Zhu YH, Xu JQ, Matlin SA, et al. (May 1990). "Comparative cross-over pharmacokinetic study on two types of postcoital contraceptive tablets containing levonorgestrel". Contraception. 41 (5): 557–567. doi:10.1016/0010-7824(90)90064-3. PMID   2112080.
220. "Estrace: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 6 September 2024.
221. Kuhl H, Wiegratz I (1 January 2008). Klimakterium, Postmenopause und Hormonsubstitution[Climacteric, Postmenopause and Hormone Replacement] (in German) (4 ed.). UNI-MED-Verlag. p. 18. ISBN   978-3-83742-043-2. With Progynon Depot-10, an oily solution of 10 mg estradiol valerate, an injection preparation had been available since 1953 and since 1966 coated tablets with estradiol valerate for oral therapy. The first Schering preparation containing micronized estradiol was marketed in 1968 as Progynova 21 (2 mg) and Progynova 21 mite (1 mg).
222. Rigg LA, Milanes B, Villanueva B, Yen SS (December 1977). "Efficacy of intravaginal and intranasal administration of micronized estradiol-17beta". The Journal of Clinical Endocrinology and Metabolism. 45 (6): 1261–1264. doi: 10.1210/jcem-45-6-1261 . PMID   591620.
223. Yoo JW, Lee CH (May 2006). "Drug delivery systems for hormone therapy". Journal of Controlled Release. 112 (1): 1–14. doi:10.1016/j.jconrel.2006.01.021. PMID   16530874. Transdermal gels. The first system used for estrogen delivery through skin was the application of estrogen dissolved into a water–alcohol solvent in a form of gel for the treatment of postmenopausal symptoms [80] [...] EstroGel (Solvay) has been in the Europe market for more than 25 years, but approved in the US only in 2004. EstroGel contains 17β-estradiol in a hydro-alcoholic gel base which renders a controlled release profile. [...] Estrasorb (Novavax, Malvern, PA) is launched in 2003 as the first topical, lotion-like nanoemulsion for the treatment of vasomotor symptoms. [...] Conventional reservoir patches. The first transdermal patch for HT was Estraderm (Novartis, Switzerland) which was launched in Europe in 1985 and has been widely used ever since. [...] Transdermal matrix patches. [...] Climara (Berlex, Montville, NJ) was first introduced as the matrix patch in 1995. A year later, Vivelle (Novogyne, Miami, FL) was introduced in the market [...]
224. Davis SR, Dinatale I, Rivera-Woll L, Davison S (May 2005). "Postmenopausal hormone therapy: from monkey glands to transdermal patches". The Journal of Endocrinology. 185 (2): 207–222. doi: 10.1677/joe.1.05847 . PMID   15845914. One of the earliest reports of the novel transdermal patch delivery system for oestradiol was published in 1983 (Laufer et al. 1983).
225. Benson HA, Watkinson AC (2011). Benson HA, Watkinson AC (eds.). Transdermal and Topical Drug Delivery Today. Wiley. doi:10.1002/9781118140505. ISBN   9781118140505. Table 18.1 Passive Transdermal Drugs for Systemic Drug Delivery Launched in the United States and Europe [...] Drug: Estradiol. Indication: Female HRT. U.S. approval: 1986. Marketed in the EU: Yes.
226. Prausnitz MR, Mitragotri S, Langer R (February 2004). "Current status and future potential of transdermal drug delivery". Nature Reviews. Drug Discovery. 3 (2): 115–124. doi:10.1038/nrd1304. PMID   15040576. S2CID   28888964. Timeline: Important events in transdermal drug delivery: [...] 1986: Estraderm (17β-oestradiol) patch, FDA approval for hormone replacement.
227. Pastore MN, Kalia YN, Horstmann M, Roberts MS (May 2015). "Transdermal patches: history, development and pharmacology". British Journal of Pharmacology. 172 (9): 2179–2209. doi:10.1111/bph.13059. PMC   4403087 . PMID   25560046.
228. Oettel M, Schillinger E (6 December 2012). Estrogens and Antiestrogens I: Physiology and Mechanisms of Action of Estrogens and Antiestrogens. Springer Science & Business Media. pp. 7–8. ISBN   978-3-642-58616-3.
229. Mosby's GenRx: A Comprehensive Reference for Generic and Brand Prescription Drugs. Mosby. 2001. p. 944. ISBN   978-0-323-00629-3.
230. Astedt B, Svanberg L, Jeppsson S, Liedholm P, Rannevik G (January 1977). "The natural oestrogenic hormone oestradiol as a new component of combined oral contraceptives". British Medical Journal. 1 (6056): 269. doi:10.1136/bmj.1.6056.269. PMC   1604185 . PMID   319864.
231. Christin-Maitre S (February 2013). "History of oral contraceptive drugs and their use worldwide". Best Practice & Research. Clinical Endocrinology & Metabolism. 27 (1): 3–12. doi:10.1016/j.beem.2012.11.004. PMID   23384741.
232. Farris M, Bastianelli C, Rosato E, Brosens I, Benagiano G (October 2017). "Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis". Expert Review of Clinical Pharmacology. 10 (10): 1129–1144. doi:10.1080/17512433.2017.1356718. PMID   28712325. S2CID   205931204.
233. Alsina JC (February 2010). "After 50 years of ethinylestradiol, another oestrogen in combined oral contraceptives". The European Journal of Contraception & Reproductive Health Care. 15 (1): 1–3. doi:10.3109/13625180903585431. PMID   20136565. S2CID   9642823.
234. Chabbert-Buffet N, Gerris J, Jamin C, Lello S, Lete I, Lobo P, et al. (October 2013). "Toward a new concept of "natural balance" in oral estroprogestin contraception". Gynecological Endocrinology. 29 (10): 891–896. doi:10.3109/09513590.2013.824963. PMID   23931030. S2CID   207489327.
235. Fruzzetti F, Bitzer J (January 2010). "Review of clinical experience with estradiol in combined oral contraceptives". Contraception. 81 (1): 8–15. doi:10.1016/j.contraception.2009.08.010. PMID   20004267.
236. Fruzzetti F, Trémollieres F, Bitzer J (May 2012). "An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest". Gynecological Endocrinology. 28 (5): 400–408. doi:10.3109/09513590.2012.662547. PMC   3399636 . PMID   22468839.
237. "Estradiol". Archived from the original on 18 June 2018. Retrieved 27 November 2016.
238. Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 206–. ISBN   978-94-011-4439-1.
239. "KEGG DRUG: Estradiol". Archived from the original on 28 November 2016. Retrieved 30 November 2016.
240. Rowlands S (January 2009). "New technologies in contraception" (PDF). BJOG. 116 (2): 230–239. doi:10.1111/j.1471-0528.2008.01985.x. PMID   19076955. S2CID   3415547. Archived (PDF) from the original on 28 August 2021. Retrieved 9 December 2019.
241. Ashley F (23 July 2020). "Surgical Informed Consent and Recognizing a Perioperative Duty to Disclose in Transgender Health Care" (PDF). McGill Journal of Law and Health: 75. SSRN   3633573 . Retrieved 19 May 2023.
242. Sweetman, Sean C., ed. (2009). "Sex hormones and their modulators". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. p. 2097. ISBN   978-0-85369-840-1. Archived from the original on 10 June 2022. Retrieved 1 March 2018.
243. "IBM Watson Health Products: Please Login". Archived from the original on 18 August 2020. Retrieved 10 June 2022.
244. Kollewe J (24 September 2022). "HRT: inside the complex global supply chain behind a $20bn market". The Guardian . Retrieved 16 May 2024.
245. Miles D (1 March 2024). "Women 'tearing their hair out' amid continuing global shortage of vital menopause medication". ABC News . Retrieved 16 May 2024.
246. Swift M (22 March 2024). "Women resorting to desperate measures amid menopause medication shortage". Newshub . Retrieved 16 May 2024.
247. "FDA-Approved Drugs, New Drug Application 010753". Drugs@FDA. Archived from the original on 21 March 2021. Retrieved 16 January 2021.
248. "Estradiol/Progesterone - TherapeuticsMD - AdisInsight". Archived from the original on 22 October 2016. Retrieved 27 November 2016.
249. Pickar JH, Bon C, Amadio JM, Mirkin S, Bernick B (December 2015). "Pharmacokinetics of the first combination 17β-estradiol/progesterone capsule in clinical development for menopausal hormone therapy". Menopause. 22 (12): 1308–1316. doi:10.1097/GME.0000000000000467. PMC   4666011 . PMID   25944519.
250. Kaunitz AM, Kaunitz JD (September 2015). "Compounded bioidentical hormone therapy: time for a reality check?". Menopause. 22 (9): 919–920. doi:10.1097/GME.0000000000000484. PMID   26035149.
251. Pinkerton JV, Pickar JH (February 2016). "Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy". Menopause. 23 (2): 215–223. doi:10.1097/GME.0000000000000523. PMC   4927324 . PMID   26418479.
252. Fugh-Berman A, Bythrow J (July 2007). "Bioidentical hormones for menopausal hormone therapy: variation on a theme". Journal of General Internal Medicine. 22 (7): 1030–1034. doi:10.1007/s11606-007-0141-4. PMC   2219716 . PMID   17549577.
253. Melville C (22 September 2015). Sexual and Reproductive Health at a Glance. Wiley. pp. 108–. ISBN   978-1-119-23516-3. Archived from the original on 10 June 2022. Retrieved 17 February 2019.
254. Dollery CT (1991). Therapeutic Drugs. Churchill Livingstone. ISBN   9780443028465. Archived from the original on 11 April 2022. Retrieved 17 February 2019. Parenteral preparations 1. Oestradiol implants (Organon, UK) are sterilized pellets containing 25, 50 or 100 mg. They are supplied individually in glass tubes.
255. Kar A (2005). Medicinal Chemistry. New Age International. pp. 614–. ISBN   978-81-224-1565-0. Archived from the original on 10 June 2022. Retrieved 17 February 2019. Oestradiol Implants(R) (Organon, U.K.). Dose. [...] implantation, 20 to 100 mg.
256. Walters WA (10 July 1986). Transsexualism and sex reassignment. Oxford University Press. p. 159. ISBN   978-0-19-554462-6. Archived from the original on 10 June 2022. Retrieved 17 February 2019. 2. Injections or implants [...] Oestradiol Implants (Organon) 20 mg pellets. 50 mg pellets. 100 mg pellets.
257. Braam WJ (2006). Broze botten. Inmerc. pp. 79–. ISBN   978-90-6611-844-7. Archived from the original on 10 June 2022. Retrieved 17 February 2019.
258. https://www.gezondheidsnet.nl/medicijnen/meno-implantr%5B%5D
259. Eskin BA (1988). The Menopause: Comprehensive Management. Macmillan. p. 278. ISBN   978-0-02-334230-1. Archived from the original on 10 June 2022. Retrieved 17 February 2019. Estradiol Pellets — (Progynon Pellets — Progynon Associates), 25 mg (Estropel Pellets — Bartor Pharmacal).
260. American Medical Association. Dept. of Drugs, Council on Drugs (American Medical Association), American Society for Clinical Pharmacology and Therapeutics (1 February 1977). "Estrogens, Progestagens, Oral Contraceptives, and Ovulatory Agents". AMA drug evaluations. Publishing Sciences Group. pp. 540–572. ISBN   978-0-88416-175-2. Archived from the original on 1 August 2020. Retrieved 17 February 2019. Subcutaneous implantation: (Estradiol) One 25 mg pellet every three to four months or two 25 mg pellets every four to six months. Preparations. Progynon (Schering). Implantation: Pellets 25 mg.
261. Jones JM (1979). Physicians' Desk Reference. Medical Economics Company. p. 1508. Archived from the original on 10 June 2022. Retrieved 17 February 2019. PROGYNON Pellets for subcutaneous implantation are cylindrical in shape with an approximate diameter of 3.2 mm. and length of 3.5 mm. Each PROGYNON Pellet contains 25 mg. estradiol.
262. Birkhauser M, Barlow D, Notelovitz M, Rees M (12 August 2005). Health Plan for the Adult Woman: Management Handbook. CRC Press. pp. 27–. ISBN   978-0-203-49009-9. Archived from the original on 10 June 2022. Retrieved 17 February 2019.
263. Pinkerton JV (December 2014). "What are the concerns about custom-compounded "bioidentical" hormone therapy?". Menopause. 21 (12): 1298–1300. doi:10.1097/GME.0000000000000376. PMID   25387347.
264. Santoro N, Braunstein GD, Butts CL, Martin KA, McDermott M, Pinkerton JV (April 2016). "Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientific Statement". The Journal of Clinical Endocrinology and Metabolism. 101 (4): 1318–1343. doi: 10.1210/jc.2016-1271 . PMID   27032319. S2CID   33802990.
265. "Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms". JAMA. 322 (12): 1206–1207. September 2019. doi:10.1001/jama.2019.10692. PMID   31550026. S2CID   202748463.
266. Garza-Flores J (April 1994). "Pharmacokinetics of once-a-month injectable contraceptives". Contraception. 49 (4): 347–359. doi:10.1016/0010-7824(94)90032-9. PMID   8013219.
267. Koetsawang S (April 1994). "Once-a-month injectable contraceptives: efficacy and reasons for discontinuation". Contraception. 49 (4): 387–398. doi:10.1016/0010-7824(94)90034-5. PMID   8013221.
268. Toppozada MK (April 1994). "Existing once-a-month combined injectable contraceptives". Contraception. 49 (4): 293–301. doi:10.1016/0010-7824(94)90029-9. PMID   8013216.
269. Toppozada MK (1983). "Monthly Injectable Contraceptives". In Alfredo Goldsmith, Mokhtar Toppozada (eds.). Long-Acting Contraception. pp. 93–103. OCLC   35018604. Archived from the original on 10 June 2022. Retrieved 27 December 2019.
270. Gentile S (December 2005). "The role of estrogen therapy in postpartum psychiatric disorders: an update". CNS Spectrums. 10 (12): 944–952. doi:10.1017/S1092852900010518. PMID   16344831. S2CID   24450591.
271. Ng RC, Hirata CK, Yeung W, Haller E, Finley PR (September 2010). "Pharmacologic treatment for postpartum depression: a systematic review". Pharmacotherapy. 30 (9): 928–941. doi:10.1592/phco.30.9.928. PMID   20795848. S2CID   23053672.
272. di Scalea TL, Wisner KL (November 2009). "Pharmacotherapy of postpartum depression". Expert Opinion on Pharmacotherapy. 10 (16): 2593–2607. doi:10.1517/14656560903277202. PMC   2929691 . PMID   19874247.
273. Moses-Kolko EL, Berga SL, Kalro B, Sit DK, Wisner KL (September 2009). "Transdermal estradiol for postpartum depression: a promising treatment option". Clinical Obstetrics and Gynecology. 52 (3): 516–529. doi:10.1097/GRF.0b013e3181b5a395. PMC   2782667 . PMID   19661765.
274. Sharma V (October 2003). "Pharmacotherapy of postpartum psychosis". Expert Opinion on Pharmacotherapy. 4 (10): 1651–1658. doi:10.1517/14656566.4.10.1651. PMID   14521476. S2CID   23193276.
275. Cappelletti M, Wallen K (February 2016). "Increasing women's sexual desire: The comparative effectiveness of estrogens and androgens". Hormones and Behavior. 78: 178–193. doi:10.1016/j.yhbeh.2015.11.003. PMC   4720522 . PMID   26589379.
276. Santoro N, Worsley R, Miller KK, Parish SJ, Davis SR (March 2016). "Role of Estrogens and Estrogen-Like Compounds in Female Sexual Function and Dysfunction". The Journal of Sexual Medicine. 13 (3): 305–316. doi:10.1016/j.jsxm.2015.11.015. PMID   26944462.
277. Crider A, Pillai A (January 2017). "Estrogen Signaling as a Therapeutic Target in Neurodevelopmental Disorders". The Journal of Pharmacology and Experimental Therapeutics. 360 (1): 48–58. doi:10.1124/jpet.116.237412. PMC   5193073 . PMID   27789681.

Further reading

• Kuhl H (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID   16112947. S2CID   24616324.
• Oettel M, Schillinger E (6 December 2012). Estrogens and Antiestrogens I: Physiology and Mechanisms of Action of Estrogens and Antiestrogens. Springer Science & Business Media. ISBN   978-3-642-58616-3.
• Oettel M, Schillinger E (6 December 2012). Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen. Springer Science & Business Media. ISBN   978-3-642-60107-1.
• Fruzzetti F, Trémollieres F, Bitzer J (May 2012). "An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest". Gynecological Endocrinology. 28 (5): 400–408. doi:10.3109/09513590.2012.662547. PMC   3399636 . PMID   22468839.
• Stanczyk FZ, Archer DF, Bhavnani BR (June 2013). "Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment". Contraception. 87 (6): 706–727. doi:10.1016/j.contraception.2012.12.011. PMID   23375353.

External links

• "Estradiol Topical: MedlinePlus Drug Information". MedlinePlus.
• "Estradiol Transdermal Patch: MedlinePlus Drug Information". MedlinePlus.